Programming Available for Nurses

If you have an account with CPNP.org, please log in before attempting to register. By logging in, the system can help you make informed selections based on credits currently on your transcript.

Active Dates Title Hours Register
08/13/2015 - 08/13/2016 Putting Naloxone Into Action! ACPE
Prescription drug and opioid overdoses continue to rise in the U.S. Communities with Overdose Education and Naloxone Distribution ...[more]

Prescription drug and opioid overdoses continue to rise in the U.S. Communities with Overdose Education and Naloxone Distribution (OEND) programs have demonstrated how effective this practice can be in the number of lives reported to have been saved. Legislation to allow access to naloxone for non-medical people has also been passed by many states. Since naloxone remains a prescription medication, pharmacists have an important role in facilitating access to this potentially life-saving medication. Many pharmacists are already incorporating OEND into their practice, but opportunities for expanding OEND practice remain. Expert presenters will present the various models they have implemented to increase Naloxone distribution within their practice setting.

learn more

1.0 Continue to the course
04/05/2017 - 04/05/2018 Developing a Treatment Plan for Insomnia When First-Line Options Fail ACPE 2.8 FREE!
01/24/2017 - 01/24/2018 Binge-Eating Disorder: Developing a Treatment Plan for Binge-Eating Disorder When First-Line Options Fail ACPE 2.2 FREE!
06/13/2016 - 04/18/2019 Alcohol Use Disorder Pharmacotherapy: Old and New ACPE
Alcohol use disorder has significant medical and social impact on the US healthcare system, accounting for 88,000 deaths per year ...[more]

Alcohol use disorder has significant medical and social impact on the US healthcare system, accounting for 88,000 deaths per year and more than $250 billion in annual costs. Despite medications which are FDA approved to treat alcohol use disorder, studies consistently show rates of use of less than 10% with some being less than 5%. This program is intended to provide the learner with information on FDA approved medications and medications used off label in the treatment of alcohol use disorders.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 At the Eleventh Hour: Will New Antidepressants Save the Day? ACPE
New medications and mechanisms for the treatment of depression have come into the picture in the past 3-5 years. For many years, ...[more]

New medications and mechanisms for the treatment of depression have come into the picture in the past 3-5 years. For many years, serotonergic drugs have been the treatment of choice for major depressive disorder. With the exception of bupropion and mirtazapine, the most common mechanism of action for antidepressants has been to inhibit the reuptake of serotonin.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/20/2019 Brain, Genes, Medication and the Lifetime Course of Attention Deficit Hyperactivity Disorder ACPE
While many children with Attention Deficit Hyperactivity Disorder will ‘grow out’ of the disorder, many do not and the ...[more]

While many children with Attention Deficit Hyperactivity Disorder will ‘grow out’ of the disorder, many do not and the full syndrome persists into adulthood in around 20-40%. We do not understand why childhood ADHD has such a variable outcome, partly as childhood clinical, demographic and neuropsychological characteristics are very weak predictors of outcome. This talk thus considers how neuroimaging and genomics can inform our understanding of the neurobiology of this highly variable lifetime course of this highly prevalent disorder. It will also consider whether psychostimulants, which are commonly prescribed for the disorder, impact the long-term course of the disorder.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Current Understanding and Management of Parkinson’s Disease: Five New Things ACPE
With the expected increase in PD as the population ages, knowledge of PD management will allow pharmacists to better optimize care. ...[more]

With the expected increase in PD as the population ages, knowledge of PD management will allow pharmacists to better optimize care. In recent years, advances in the basic and clinical sciences has yielded substantive new information which are relevant for the management of Parkinson disease. Management of Parkinson’s disease is becoming more complex. New information is available on biomarkers, motor and nonmotor symptoms, medications, management guidelines, and results of long-term studies for disease modification.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 Hematologic Issues and Antipsychotic Medications: Overview and Management ACPE
Antipsychotics are associated with a variety of side effects and include the potential for hematologic issues and blood dyscrasias. ...[more]

Antipsychotics are associated with a variety of side effects and include the potential for hematologic issues and blood dyscrasias. Severe neutropenia (formally agranulocytosis) is the most recognized side effect known to occur with clozapine and for which a rigid system of monitoring in the US has been developed. In addition, some patient populations such as patients of African or Middle Eastern descent are known to have differences in normative data ranges which were largely developed in European populations.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Illicit Substance Use in Adolescence and Young Adulthood: New and Emerging Substances and Treatment Strategies ACPE
Illicit substance use among adolescents and young adults continues to be of growing concern and has been associated with the ...[more]

Illicit substance use among adolescents and young adults continues to be of growing concern and has been associated with the development of other psychiatric disorders. Due to generational differences, treatment approaches for this patient population may need to differ than those commonly used with older adults. It is critical for neuropsychiatric pharmacists to stay current with new and emerging treatment strategies (e.g. technology-based, pharmacological) to better enhance the recovery of younger patients with substance use disorders.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 I’ll Rise But I Can’t Shine: A Case-based Approach to Chronic Pain and Impairment of Sleep ACPE
Sleep disturbance is perhaps one of the most prevalent complaints of patients with chronically painful conditions. Experimental ...[more]

Sleep disturbance is perhaps one of the most prevalent complaints of patients with chronically painful conditions. Experimental studies of healthy subjects and cross-sectional research in clinical populations suggest the possibility that the relationship between sleep disturbance and pain might be reciprocal, such that pain disturbs sleep continuity/quality and poor sleep further exacerbates pain. This suggests that aggressive management of sleep disturbance may be an important treatment objective with possible benefits beyond the improvement in sleep.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Looking Beyond the Smoke and Mirrors: A Review of Electronic Cigarettes ACPE
Promoted as a safer and cheaper alternative to conventional cigarettes, the use of ECs has grown rapidly, while the scientific ...[more]

Promoted as a safer and cheaper alternative to conventional cigarettes, the use of ECs has grown rapidly, while the scientific evidence supporting these claims is both inconclusive and controversial.  Pharmacists are routinely involved in the medication management and education of patients interested in smoking cessation. A greater understanding of the components of ECs, how this compares to traditional cigarettes, how ECs may or may not aid in smoking cessation efforts, and public health risks is needed.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 Managing Diversion, Misuse and Abuse of Stimulants ACPE
Attention-deficit/ hyperactivity disorder (ADHD) is the most commonly diagnosed childhood disorder. Between 1995 and 2008, ...[more]

Attention-deficit/ hyperactivity disorder (ADHD) is the most commonly diagnosed childhood disorder. Between 1995 and 2008, stimulants prescribed to treat ADHD increased six-fold among adults in the United States. While these medications are the most effective pharmacotherapy treatment for ADHD, there are risks and cautions associated with use. 

Pharmaceutical stimulants, similar to illicit psychostimulants, have the potential to induce abuse and dependence. This session will address the increase in reports related to stimulant misuse, abuse, and diversion within ADHD.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 mHealth and the Treatment of Serious Mental Illness ACPE
Innovative Mobile health (mHealth) approaches are revolutionizing the way we study, assess, and treat mental illness. mHealth may ...[more]

Innovative Mobile health (mHealth) approaches are revolutionizing the way we study, assess, and treat mental illness. mHealth may aid in closing access gaps to services, reducing hospitalizations, improving consistency and accuracy of care, and reducing healthcare expenditures. However, the lack of regulations into whom may develop an mHealth app and paucity of clinical evidence means some caution should be exercised. Clinicians need guidance on the proposed advantages and disadvantages of these new technologies and how mHealth integration can be effectively incorporated into practice.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 Navigating the FDA Label Changes for Pregnancy and Lactation Risks Associated with Medications ACPE
Patients are often asking pharmacists for harm information about medications and looking for a black and white answer. This is a ...[more]

Patients are often asking pharmacists for harm information about medications and looking for a black and white answer. This is a gray area and the new pregnancy/lactation labeling changes adds to this clinical conundrum. Guidance on how to best present and discuss this information with patients, especially those on psychiatric medications is needed.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 Pandora’s Box Defusing the Danger of Drug Interactions with Psychoactive Medications ACPE
Key drug-drug interactions involving psychotropic medications are important to identify in practice. However, it is critical for ...[more]

Key drug-drug interactions involving psychotropic medications are important to identify in practice. However, it is critical for healthcare providers to be able to recognize which drug-drug interactions are more likely to result in clinically significant events and to understand which individual patient characteristics may increase risk for experiencing certain adverse effects. This session will allow participants to identify both psychotropic medications more commonly implicated in drug-drug interactions as well as the clinical significance of these interactions.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Psychiatry and Neurology Pharmacogenomics: A Closer look at Clinical Application ACPE
This session will focus on translating available information on genetic testing and applying this information to clinical practice. ...[more]

This session will focus on translating available information on genetic testing and applying this information to clinical practice. The speaker will take a case-based approach to help pharmacists effectively utilize genetic testing as a tool to be incorporated into the clinical decision-making process.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Psychiatry and Neurology Pharmacogenomics: Implications for Patient Care and Resources for Implementation ACPE
Numerous questions remain unanswered and there is much debate regarding the utility of pharmacogenetic (PG) testing in clinical ...[more]

Numerous questions remain unanswered and there is much debate regarding the utility of pharmacogenetic (PG) testing in clinical practice. In this session, an introduction to pharmacogenomics will be presented to the attendees. In particular, the benefits and limitations of pharmacogenomics in psychiatry and neurology will be discussed. Additionally, resources will be identified to assist pharmacists with implementing pharmacogenomics into patient care.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/19/2019 Psychogenic Disorders in Neurology: Not Just in your Head ACPE
Somatoform disorders/conversion disorders/functional disorders in neurology [e.g., no-nepileptic seizures (NES)] are common and ...[more]

Somatoform disorders/conversion disorders/functional disorders in neurology [e.g., no-nepileptic seizures (NES)] are common and mimic neurologic conditions (e.g. epilepsy) but in the absence of abnormal electrical discharges. These disorders are disabling and are not adequately recognized or treated by mental health professionals including pharmacists. Management of these disorders is complex and requires a multidisciplinary management approach.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/20/2019 Second Generation Antipsychotic Long-acting Injectables: Potential Benefits and Obstacles to Appropriate and Effective Utilization ACPE
There are a lack of studies comparing the differences among second generation long-acting injectables (SGA LAIs) and limited ...[more]

There are a lack of studies comparing the differences among second generation long-acting injectables (SGA LAIs) and limited guidelines to help clinicians choose the most appropriate agents for each individual, particularly given the availability of newer agents. Also insufficient are epidemiological data on re-hospitalization and adherence rates amongst the different SGA LAIs. Barriers, including cost and acceptance, may further limit the use of these agents and it is important that strategies to overcome these barriers be identified.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 The Alphabet Soup of Regulatory and Quality Measures-Are You Up to Date? ACPE
Behavioral health, similar to many areas of healthcare, is regulated by many agencies. Clinical pharmacy practitioners are not ...[more]

Behavioral health, similar to many areas of healthcare, is regulated by many agencies. Clinical pharmacy practitioners are not always well acquainted with the regulatory standards and quality measures that determine accreditation and reimbursement status at the organizations in which they are employed. The alphabet soup of acronyms impacting behavioral health include TJC’s HBIPS & NPSG, CMS, PQA, VA-SAIL.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/18/2019 The Role of Microbiota in Health and Disease: The Emerging Gut-Brain Connection ACPE
The human indigenous microbiota are an essential component of the modern concept of human health and emerging data suggest a role ...[more]

The human indigenous microbiota are an essential component of the modern concept of human health and emerging data suggest a role of the microbiome in human disease through physiologic, immunologic and metabolic pathways. This keynote will deliver an overview of the microbiota in human health in disease and an overview of how modulation through treatments could change the microbiome and possible course of disease with some focus on mental health. This is a cutting edge topic and many health care providers are not aware of the research and current explosion of work in this area.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
06/13/2016 - 04/20/2019 Vitamin Supplementation in Schizophrenia Treatment ACPE
Schizophrenia is a chronic illness characterized by positive symptoms, negative symptoms and impairments in neurocognition. ...[more]

Schizophrenia is a chronic illness characterized by positive symptoms, negative symptoms and impairments in neurocognition. Antipsychotics are the mainstay of treatment however we do not yet fully understand the pathophysiology of schizophrenia or if dopamine is a primary neurotransmitter or only as secondary messenger in the etiology of the illness. Environmental factors such as diet and vitamins have been shown to be associated with schizophrenia. This has been found during the illness but also during prenatal development when deficiencies in vitamins may play a key role in neurodevelopment. Growing evidence suggests that vitamin levels are lower in schizophrenia compared to healthy controls. Thus, vitamins may have a role in schizophrenia. Furthermore, accumulating evidence suggests that genetic polymorphisms or subgroup factors that may contribute to greater treatment response for symptoms in people with schizophrenia. This talk will focus on the role of vitamins in schizophrenia and will focus on understanding patient factors that may have a greater treatment response.

learn more

1.0
Non-member rate:
$30.00
Member rate: $25.00, login
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Anxiety and Anxiety-Related Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of anxiety disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of anxiety disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Biostatistics and Research Design in Psychiatry ACPE
This self-study course is designed to assist the learner in selecting and evaluating sources for biomedical information appropriate ...[more]

This self-study course is designed to assist the learner in selecting and evaluating sources for biomedical information appropriate for psychiatric pharmacy practice. Content includes a comprehensive outline with focus on how to critically evaluate a study with regard to design and methodology, sources of bias, and significance and applicability of findings.

 

learn more

1.5 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Bipolar Disorder ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of bipolar disorder. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of bipolar disorder. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Depression ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of depression. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of depression. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Economic and Outcome Studies in Psychiatry ACPE
This self-study course focuses on understanding and interpreting pharmacoeconomic studies. Using a comprehensive outline, learners ...[more]

This self-study course focuses on understanding and interpreting pharmacoeconomic studies. Using a comprehensive outline, learners will understand the difference between efficacy and effectiveness studies and the different types of pharmacoeconomic studies. Focus will be placed on the different types of outcomes, the features of decision and sensitivity analysis, the key features of meta-analyses and the common statistical analyses included in a meta-analysis.

learn more

1.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Neurocognitive Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of elderly psychiatric issues. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of elderly psychiatric issues. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.
 

learn more

1.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of pediatric related diseases. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of pediatric related diseases. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Neurologic Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of neurologic disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of neurologic disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Personality Disorders and Eating Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of personality disorders and eating disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of personality disorders and eating disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Regulatory Issues in Pharmacy Practice ACPE
This self-study course focuses on understanding compliance requirement standards established by national accrediting and regulatory ...[more]

This self-study course focuses on understanding compliance requirement standards established by national accrediting and regulatory agencies. Content includes a comprehensive outline on topics such as Pharmacy and Therapeutics Committee, formulary management, Medication Use Evaluation, and performance improvement cycles are described. The Joint Commission standards, State Operations Manual F-tags and the roles of IRBs and various governmental agencies are also addressed in this course.

learn more

1.5 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Schizophrenia Spectrum and Other Psychotic Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of schizophrenia and movement disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of schizophrenia and movement disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Sleep-Wake Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of sleep disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of sleep disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5 $50.00
01/13/2016 - 01/13/2018 2016-2017 Psychiatric Pharmacotherapy Review Course-Substance-Related Disorders ACPE
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of substance use disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of substance use disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5 $50.00
08/31/2015 - 08/31/2018 Managing Treatment Resistant ADHD: The Case of the Unwanted Side Effects ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant attention-deficit/hyperactivy disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
08/14/2015 - 08/14/2018 Developing a First-Line Attention-Deficit/Hyperactivity (ADHD) Treatment Plan: A Case of Stimulant or No Stimulant? ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of attention-deficit/hyperactivity disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated attention-deficit/hyperactivity disorder. The course will require 1 hour for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5 $15.00
08/03/2015 - 08/03/2018 Treatment Resistant Generalized Anxiety Disorder: A Case of the Intolerable Adjunctive Medication ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant generalized anxiety disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
07/01/2015 - 07/01/2018 Implementing Second-Line and Third-Line Alcohol Use Disorder Therapies: The Case of the Nightcap ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based strategies for the management of complex or treatment-resistant alcohol use disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
07/01/2015 - 07/01/2018 Implementing Second-Line and Third-Line Therapies for Attention Deficit Hyperactivity Disorder: The Case of the Unfocused Student ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of attention deficity hyperactivity disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with attention deficity hyperactivity disorder will also be emphasized.

learn more

1.5 $15.00
07/01/2015 - 07/01/2018 Implementing Second-Line and Third-Line Therapies for Insomnia: The Case of the Grieving Widower ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of insomnia. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with insomnia will also be emphasized.

learn more

1.5 $15.00
06/19/2015 - 04/20/2018 ACA and Mental Health Care: Can We Deliver? ACPE
The Affordable Care Act (ACA) made mental and behavioral health treatment one of 10 essential benefits required in new insurance ...[more]

The Affordable Care Act (ACA) made mental and behavioral health treatment one of 10 essential benefits required in new insurance policies and was expected to yield comprehensive coverage of mental illness equal to that of medical and surgical needs. However, many of those seeking treatment are finding shortages of mental health providers and treatment facilities, as well as gaps in insurance coverage. Yet with the advent of “whole patient” accountable care, a new set of economic incentives are transforming the larger health care system, and new collaborations and economic incentives are emerging, often with the desire to provide comprehensive medication management and coordination services. Drs. Joseph Parks and Troy Trygstad will discuss the impact of the ACA on mental health care and gaps in service delivery from the perspective of two different health care eco-systems and their innovative approaches to mental health care delivery.

learn more

1.5 $15.00
06/19/2015 - 04/21/2018 Approaches to Treating Depression in Patients with Cancer ACPE
Up to a quarter of patients with cancer suffer from depression that may go unrecognized, affecting their quality of life. ...[more]

Up to a quarter of patients with cancer suffer from depression that may go unrecognized, affecting their quality of life. Confounding matters, many of the symptoms of depression can be often confused with side effects of cancer treatments. This session will review the literature related to depression in cancer patients and examine ways to distinguish depressive symptoms from disease or treatment related symptoms while identifying strategies for implementing appropriate therapy.

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Collaborations to Improve Care: Psychiatric and Ambulatory Care Pharmacists ACPE
Tuesday, April 21, 2015, 11:15 a.m.-12:15 p.m. Steven Chen, PharmD, FASHP, FCSHP, FNAP, Associate Professor and Chair, Titus Family ...[more]

Tuesday, April 21, 2015, 11:15 a.m.-12:15 p.m.
Steven Chen, PharmD, FASHP, FCSHP, FNAP, Associate Professor and Chair, Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, Hygeia Centennial Chair in Clinical Pharmacy, University of Southern California

The provision of care for those with comorbid mental health disorders often results in estimated costs two to three times higher than those without. The burden of providing psychiatric services cannot be met by psychiatrists alone. As such, pharmacists are increasingly being used as providers in ambulatory care and clinic settings and can be tasked with treatment of psychiatric conditions. Collaboration between psychiatric and ambulatory care pharmacists can provide benefit to patients, providers, and clinics. Dr. Steven Chen will discuss deficits in providing mental health services, the resulting cost burden to primary care clinics, how to establish an effective practice model for integrating ambulatory care and psychiatric pharmacists into primary care clinics, and how to document the collaborative interactions.

learn more

1.0 $15.00
06/19/2015 - 04/20/2018 Drug Metabolism: Beyond CYP450 ACPE
The CYP450 system is responsible for the metabolism of many psychotropic medications, and is also involved in a plethora of ...[more]

The CYP450 system is responsible for the metabolism of many psychotropic medications, and is also involved in a plethora of drug-drug interactions. Due to its prominence in drug metabolism and drug-drug interactions, it is the most well-known system of drug metabolism. There are, however, other enzyme systems responsible for drug metabolism, such as those involved in Phase II metabolism, which often get overlooked. These enzyme systems are involved in the metabolism of many psychotropic drugs and each of these enzymes has inducers, inhibitors, and substrates, many of which are psychotropic medications. A good understanding of these enzyme systems are crucial in recognizing potential drug interactions.

learn more

1.0 $15.00
06/19/2015 - 04/20/2018 Getting High on Knowledge: An Update on Substance Abuse ACPE
According to the results from the 2012 National Survey on Drug Use and Health (NSDUH) - Mental Health Findings report, the ...[more]

According to the results from the 2012 National Survey on Drug Use and Health (NSDUH) - Mental Health Findings report, the relationship between increased substance abuse and acute mental illness is starkly clear. Greater than 10% of the U.S. adult population reported illicit substance use in the past year, a number that more than doubled to 26.7% for the adult mental health population. This disparity was consistent regardless of the type of substance being abused, whether illegal agents (i.e., heroin, cocaine) or non-medical use of prescription drugs.

learn more

1.0 $15.00
06/19/2015 - 04/19/2018 Medical Mimics: Differential Diagnosis of Psychotic Symptoms ACPE
Psychiatric disorders and medical conditions often have symptoms which present in a similar manner. When considering a psychiatric ...[more]

Psychiatric disorders and medical conditions often have symptoms which present in a similar manner. When considering a psychiatric diagnosis, one should always be aware of the possibility of medical conditions contributing to or causing the clinical presentation. A more thorough knowledge of medical conditions with psychotic features will enable psychiatric pharmacists and other practitioners to recommend appropriate evaluative measures in patients presenting with psychosis. This knowledge will also assist pharmacists with recommending the best choices for pharmacotherapy and non-pharmacological interventions in patients with psychosis from medical conditions.

learn more

1.0 $15.00
06/19/2015 - 04/22/2018 Medications Used to Treat Mood Disorders in Pregnancy: Controversies and Clinical Dilemmas ACPE
Treatment of mood disorders during pregnancy can be complicated and leave clinicians questioning what the best medications to ...[more]

Treatment of mood disorders during pregnancy can be complicated and leave clinicians questioning what the best medications to pregnant women should be. Dr. Marlene Freeman will discuss current clinical controversies surrounding psychiatric medications used in the treatment of mood disorders during pregnancy. She will also discuss the risk versus benefit of using psychiatric medications in women of childbearing age and pregnancy. The goal of this presentation will be to enable the audience to make effective clinical decisions and recommendations regarding the use of psychiatric medications during pregnancy and in women of childbearing age.

learn more

1.0 FREE!
06/19/2015 - 04/22/2018 New Approaches to Drug Development: Neurocircuitry Based Strategies Inspired by the Research Domain Criteria (RDoC) Initiative ACPE
Based on the wide spread failure rate of CNS clinical trials a renewed focus on early drug development is necessary. Novel study ...[more]

Based on the wide spread failure rate of CNS clinical trials a renewed focus on early drug development is necessary. Novel study designs and technologies to enhance Phase I-II studies support and de-risk Proof of Concept trials, using a ‘go no-go’ strategy. The growing application of a Research Domain Criteria (NIMH initiative) approach to drug development and patient ‘diagnosis’, along with the prioritization of behavioral, biomarker, and other neurophysiological measures demonstrating engagement in neurocircuitry of relevance might be the ‘path forward’ to successful development of new therapies for our patients with brain disorders.

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Pain Management of Co-Occurring Addiction and Chronic Pain ACPE
Chronic pain affects millions. Prescription opioid misuse and addiction among chronic pain patients are emerging public health ...[more]

Chronic pain affects millions. Prescription opioid misuse and addiction among chronic pain patients are emerging public health concerns due to dramatic increases in deaths related to overdoses. The use of opioids in the chronic non-cancer pain patient population is controversial, even more so for patients with a history of addiction. Treatment strategies include maintenance buprenorphine use and interdisciplinary pain rehabilitation programs. Evidence suggests addiction and chronic pain are interrelated and effective treatment for both is necessary for successful outcomes.

learn more

1.0 $15.00
06/19/2015 - 04/19/2018 Pharmacotherapy Issues with Gender Dysphoria ACPE
Gender Dysphoria has received increasing attention as a treatable condition as part of the transgender health care equity movement ...[more]

Gender Dysphoria has received increasing attention as a treatable condition as part of the transgender health care equity movement in the United States. According to the Diagnostic and Statistical Manual of Mental Disorders, gender dysphoria is diagnosed when an individual experiences clinically significant discomfort in their assigned gender role and wishes to live in the opposite gender role. The reported prevalence rates are 1 in 11,900 male-to-female (MTF) trans-persons and 1 in 30,400 female-to-male (FTM) trans-persons, although it appears that the rates may be higher in certain populations, such as military veterans. In many cases, patients may elect to undergo a social and physiologic change to their preferred gender. Options for undergoing this change may include exogenous cross-sex hormone administration, electrolysis, psychotherapy, and surgical interventions, all of which involve specialized knowledge by practitioners from a variety of disciplines to include pharmacy.

learn more

1.0 $15.00
06/19/2015 - 04/19/2018 Riding the Roller Coaster: Exploring the Controversy Surrounding the Diagnosis and Treatment of Bipolar Disorder in Children and Adolescents ACPE
Bipolar disorder (BD) is a recurrent and severe illness characterized by substantial symptomatic burden, comorbidity, functional ...[more]

Bipolar disorder (BD) is a recurrent and severe illness characterized by substantial symptomatic burden, comorbidity, functional impairment, and suicide risk. Childhood-onset and adolescent-onset BD may be even more severe and may have an even worse prognosis compared to adult-onset BD. Overlapping symptomatology in child and adolescent psychiatry sometimes makes the diagnosis of BD difficult to determine. Although case descriptions of mania in children have been available for almost a century, it is only within approximately the past 15 to 20 years that rigorous research on this topic has been conducted. Over the last 20 years, there has been a dramatic—up to 500%—increase in the diagnosis of BD in children and adolescents in the United States. At the same time, there was a steep rise in antipsychotic prescriptions in the United States, raising concerns that children were overdiagnosed and overprescribed potentially harmful medication. The observed increase is proposed to be unlikely because of a genuine increase in the prevalence of the disorder, but rather reflect changes in diagnostic practice. 

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Stigma and Psychiatric Disorders: Understanding and Managing Personal Biases Jointly Provided by CPNP Foundation and CPNP ACPE
Stigma surrounding psychiatric and substance use disorders can prevent individuals from seeking care and receiving potentially ...[more]

Stigma surrounding psychiatric and substance use disorders can prevent individuals from seeking care and receiving potentially life-saving treatment. Unfortunately, even health care professionals may exhibit stigma around these common disorders. During this keynote address, Dr. Friedman will discuss the prevalence of stigma amongst health care professionals, describe the impact on patient care, and offer strategies to help health care professionals recognize and manage their own personal biases.

Read a blog post by Dr. Friedman in Psychology Today

Jointly provided with the CPNP Foundation.

learn more

1.0 FREE!
06/19/2015 - 04/20/2018 The Buprenorphine Debate: An Evidence-Based Look at Current Controversies ACPE
Opioid abuse and overdose are serious public health issues within the United States. Pain reliever dependence or abuse rose from ...[more]

Opioid abuse and overdose are serious public health issues within the United States. Pain reliever dependence or abuse rose from 1.5 to 2.1 million between 2002 and 2012, and heroin dependence grew from 214,000 in 2007 to 467,000 in 2012. Drug overdose has been steadily increasing and is now the leading cause of death by injury in the US. In 2010, 75% percent of prescription overdoses involved opioid analgesics. When benzodiazepines are combined with opioids, patients are at even greater risk for morbidity and mortality.

learn more

1.0 $15.00
06/19/2015 - 04/20/2018 The Impact of Sleep Disturbances on Depression and Suicide ACPE
Insomnia has long been considered to be a symptom of psychiatric illness. This point of view has shifted and it is now codified ...[more]

Insomnia has long been considered to be a symptom of psychiatric illness. This point of view has shifted and it is now codified into several classification systems. One classification is that insomnia is to be considered a disorder in its own right. On the other hand, when insomnia occurs concurrently with other disorders it is to be considered a comorbid disorder (vs. secondary insomnia). This change has occurred primarily as a result of mounting evidence that insomnia: 1) is a risk factor for first episode depression, 2) often occurs before depression (potentially as a prodrome), 3) persists despite treatment response with antidepressant therapies, 4) is a risk factor for recurrence of depression, 5) may be successfully treated in the context of depression, and 6) treatment, at least treatment with CBT-I, appears to substantially affect the trajectory of depressive illness. Further, there is additional evidence that insomnia (and nightmares) represent a specific risk factor for suicidality (ideation, attempts, and death). This session will provide a comprehensive overview regarding sleep and depression and sleep and suicide.

learn more

1.0 $15.00
06/19/2015 - 04/20/2018 The Science of Recovery in Severe Mental Illness ACPE
Science has expanded our understanding and treatment of severe mental illnesses such that today, people with psychiatric illness ...[more]

Science has expanded our understanding and treatment of severe mental illnesses such that today, people with psychiatric illness have a real opportunity at recovery and living fulfilling lives. Dr. Lisa Dixon will present a keynote that considers the many dimensions and definitions of recovery and the importance of a new conceptualization of recovery involving illness and treatment understanding, empowerment through peers, family support, and illness management through helping others. Dr. Dixon is currently leading the innovative program OnTrackNY, a statewide initiative designed to improve outcomes and reduce disability for the population of individuals experiencing their first episode of psychosis. Her research has helped lead the way to improve recovery efforts for people suffering from severe mental illness.

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Traumatic Brain Injury: A Hard Hitting Problem ACPE
Traumatic brain injuries (TBIs) are becoming increasingly prevalent, especially given recent world events. Understanding the ...[more]

Traumatic brain injuries (TBIs) are becoming increasingly prevalent, especially given recent world events. Understanding the expanse of influence of TBI on psychiatric patient care continues to be a challenge. Individuals with TBI have been known to experience a wide variety of symptoms including depression, mania, anxiety, headache, psychosis, aggression, apathy, poor attention, memory difficulties, and poor executive functioning. In this session, Dr. Arlinghaus will define traumatic brain injury, explain the scope of issues experienced in TBI, and discuss treatment options for cognitive and behavioral symptoms related to TBI.

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Unraveling Torsades de Pointes; Implications for Clinical Practice ACPE
QT prolongation management continues to be a hot topic in psychiatric pharmacy practice, and it is imperative as the medication ...[more]

QT prolongation management continues to be a hot topic in psychiatric pharmacy practice, and it is imperative as the medication experts that we have a basic understanding of this concept and how the medications we use impact the QT interval. Dr. Allen LaPointe’s presentation will help psychiatric pharmacy specialists understand the relationship between QT interval prolongations and its implications/risk of occurrence of torsades de pointes (TdP). She will also review basic concepts in regard to QT prolongation and QT interval measurements. Finally, an overview of medications which increase risk of QT prolongation will be discussed and resources for use in QT prolongation will be presented.

learn more

1.0 $15.00
06/19/2015 - 04/21/2018 Update on Stroke Management: A Primary Care Perspective ACPE
This session will provide a summary of the most recently updated, evidence-based guidelines and recommendations on the prevention ...[more]

This session will provide a summary of the most recently updated, evidence-based guidelines and recommendations on the prevention of secondary stroke, screening assessments, and new therapies for prevention. Decision points for control of risk factors and selection of therapies will be discussed.

learn more

1.0 $15.00
06/19/2015 - 04/22/2018 Where Do We Stand with the Psychosis Risk Syndrome? ACPE
This session will provide an overview of the psychosis risk syndrome, describe initiatives and emerging data on the risk for ...[more]

This session will provide an overview of the psychosis risk syndrome, describe initiatives and emerging data on the risk for psychosis, and discuss potential treatment strategies to prevent conversion to psychosis. Dr. Diana Perkins will share her expertise in early detection of psychosis and her insight as Principal Investigator of the NIMH funded “North American Prodrome Longitudinal Study” (NAPLS2), a large multisite grant from NIMH that aims to better understand the neurobiology of early course schizophrenia and to improve psychosis risk prediction.

learn more

1.0 $15.00
05/29/2015 - 05/29/2018 Second-Line Treatments for Delirium in Older Adults ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based strategies for the management of complex or treatment-resistant delirium. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome. The course will involve review of a recommended reading(s) obtained by the participant and analysis of a patient case study via an application-based examination. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

2.0 $15.00
05/15/2015 - 05/15/2018 Managing Treatment-Resistant Social Anxiety Disorder: A Case of Co-Morbid Social Anxiety Disorder, Depression and Epilepsy ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant social anxiety disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

1.5 $15.00
05/15/2015 - 05/15/2018 The Ugly Face of Alzheimer’s Disease: Treating Behavioral and Psychiatric Symptoms in a Dementia Patient who has Failed First-Line Therapy ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of dementia. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with dementia will also be emphasized.

learn more

2.0 $15.00
04/10/2015 - 04/10/2018 Advancing CMM Practice from an Inpatient Setting
There is no ACPE credit provided for this course. The Patient Care Practice Management Community (PCPM) community hosts an ...[more]

There is no ACPE credit provided for this course.

The Patient Care Practice Management Community (PCPM) community hosts an informational session on the process of incorporating comprehensive medication management services into a psychiatric hospital. CPNP member José Scarpa, RPh, BCPP, director of pharmacy at Natchaug Hospital (Mansfield Ctr, CT) will serve as the presenter.

learn more

login
02/06/2015 - 02/06/2018 Motivational Interviewing For the Psychiatric Pharmacist login
01/23/2015 - 01/23/2016 Recovery in Major Depression: Strategies Beyond the Dopaminergic Hypothesis ACPE
Major depressive disorder (MDD) is becoming one of the most prevalent and proliferating public health concerns worldwide because of ...[more]

Major depressive disorder (MDD) is becoming one of the most prevalent and proliferating public health concerns worldwide because of its high rate of morbidity, recurrence, and associated suicide, all of which result in a profound burden to both the individual and society. Clinical pharmacists face the everyday challenge of providing individualized, safe, and effective care for patients with MDD. Through two interactive modules, this activity will review recent clinical data and guidelines in the management of MDD. Case studies will introduce potential treatment strategies, communication tools, and other data for learners to consider.

  • Module 1 will cover “The Pathogenesis of Depression: From Traditional Theories to Novel Concepts”
  • Module 2 will cover “Treatment Selection in Depression: The Role of Pharmacists in Optimizing Therapeutic Outcomes”

learn more

12/23/2014 - 12/23/2017 Side Effects, Side Effects! Are Natural Therapies Better? Second-Line Treatments for Slowing Cognitive Decline in a Patient with Alzheimer’s Disease ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of Alzheimer's disease. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with Alzheimer's disease will also be emphasized.

learn more

2.0 $15.00
12/05/2014 - 12/05/2017 Developing a First-Line Insomnia Disorder Treatment Plan: A Case of Sleeplessness in an Older Adult ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of insomnia. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated insomnia. The course will require 1 hour for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.0 Access third-party site
10/15/2014 - 10/15/2017 Developing an Obsessive-Compulsive Disorder Treatment Plan: A Case of Treatment-Resistant Obsessive-Compulsive Disorder ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant obsessive-compulsive disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
10/15/2014 - 10/15/2017 Implementing Second-Line and Third-Line Therapies for Restless Legs Syndrome: The Case of the Tired Retiree ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of restless legs syndrome. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with restless legs syndrome will also be emphasized.

learn more

2.0 $15.00
09/15/2014 - 02/27/2015 2014 Literature Analysis ACPE 2.0
Registration closed.
09/10/2014 - 09/10/2017 Managing Treatment Resistant Depression: A Case of the Despondent Accountant ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant depression. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
09/10/2014 - 09/10/2017 Managing Treatment Resistant PTSD: Managing a Case of Combat-Related PTSD with Comorbid MDD ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant post-traumatic stress disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
09/10/2014 - 09/10/2017 Treatment Resistant Panic Disorder: Managing A Case of Co-Morbid Alcohol Use Disorder ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant panic disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
08/15/2014 - 08/15/2017 Implementing Second-Line and Third-Line Social Anxiety Disorder Therapies: The Case of the Inherited Anxiety Patient ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of social anxiety disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with social anxiety disorder will also be emphasized.

learn more

2.0 $15.00
08/15/2014 - 08/15/2017 Managing Treatment Resistant Bipolar Disorder: View Behind Bipolar Lenses ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant bipolar disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
08/15/2014 - 08/15/2017 Managing Treatment Resistant Schizophrenia: A Case of Managing the Adverse Effects of Clozapine ACPE
This course is designed to provide participants with expert experience a review of evidenced-based strategies for ...[more]

This course is designed to provide participants with expert experience a review of evidenced-based strategies for the management of complex or treatment-resistant schizophrenia. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems that have a strong influence on treatment selection or outcome.

learn more

2.0 $15.00
07/01/2014 - 07/01/2017 Implementing Second-Line and Third-Line Obsessive-Compulsive Disorder (OCD) Therapies: A Case of First-Line OCD Treatment Failure ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of obsessive-compulsive disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with obsessive-compulsive disorder will also be emphasized.

learn more

2.0 $15.00
07/01/2014 - 07/01/2017 Implementing Second-Line and Third-Line Panic Disorder Therapies: A Case of Treatment Resistance and Medication-Induced Adverse Effects ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of panic disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with panic disorder will also be emphasized.

learn more

1.5 $15.00
07/01/2014 - 07/01/2017 Implementing Second-Line and Third-Line PTSD Therapies: Combat-Related PTSD Not Responding to First-Line Therapy ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of post-traumatic stress disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with post-traumatic stress disorder will also be emphasized.

learn more

1.5 $15.00
06/19/2014 - 06/19/2017 Developing a First-Line Obsessive-Compulsive Disorder Treatment Plan: A Case of Newly Diagnosed OCD ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of obsessive compulsive disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated obsessive compulsive disorder. The course will require 1.5 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5 $15.00
06/12/2014 - 04/30/2017 ADHD Across the Life Spectrum ACPE
Attention Deficit Hyperactivity Disorder can persist beyond childhood to impact the entire lifespan. Prevalence estimates vary by ...[more]

Attention Deficit Hyperactivity Disorder can persist beyond childhood to impact the entire lifespan. Prevalence estimates vary by method of study, but approximately 9 % of children meet criteria for the condition, and the condition persists into adulthood in about half of cases. Clinical trials have demonstrated the efficacy of pharmacotherapies for symptoms of attention and behavior control, with less data on broader life impact.

learn more

1.0 $15.00
06/12/2014 - 04/27/2017 Are Atypical Antipsychotics Really Mood Stabilizers? ACPE
Bipolar disorder is a common, chronic, and often disabling psychiatric condition, in which patients experience an irregular pattern ...[more]

Bipolar disorder is a common, chronic, and often disabling psychiatric condition, in which patients experience an irregular pattern of acute mood episodes and varying degrees of inter-episode recovery. Historically, medications used to treat bipolar disorder such as lithium, valproic acid, and carbamazepine were termed mood stabilizers and medications used to treat schizophrenia were termed antipsychotics. As clinical practice evolves, the increasing role for second-generation antipsychotics in the management of bipolar disorder remains controversial. In this session, two international experts will debate the issue of whether antipsychotics are truly “mood stabilizing” agents effective for the treatment of new mood episodes.

learn more

2.0
Registration closed.
06/12/2014 - 04/29/2017 Clozapine Underutilization: Overcoming Barriers to Prescribing ACPE
Clozapine is a second generation antipsychotic drug primarily used to treat the symptoms of schizophrenia in patients who have not ...[more]

Clozapine is a second generation antipsychotic drug primarily used to treat the symptoms of schizophrenia in patients who have not responded to other antipsychotic treatments. It is the only medication proven effective, approved for, and recommended for treatment-resistant schizophrenia. Despite these recommendations and current guidelines, prescription of clozapine in the U.S. is infrequent and disproportionately low (<5%) relative to the estimated prevalence of treatment-resistant schizophrenia and lower than many other countries worldwide. More appropriate prescribing of clozapine could lead to improvements in outcomes, but continued lack of use may lead to a future of suboptimal prescribing. While many barriers exist, clozapine’s low use is related in part to its frequent monitoring and serious side effects including agranulocytosis, myocarditis, seizures, sedation, obesity, diabetes mellitus and other metabolic abnormalities. This talk will review clozapine’s recommended place in therapy, treatment monitoring, and known barriers to use. In addition, it will focus on novel strategies for improving clozapine utilization and how pharmacists can play a significant role in the optimal use of this medication.

learn more

1.0
Registration closed.
06/12/2014 - 04/28/2017 Debating Medical Marijuana: Must Everyone Get Stoned to Feel Better? ACPE
The Food and Drug Administration continues to classify marijuana as a Schedule I substance, implying that it has a high potential ...[more]

The Food and Drug Administration continues to classify marijuana as a Schedule I substance, implying that it has a high potential for abuse without a currently accepted medical use. However, twenty states and the District of Columbia permit the medical use of marijuana. Colorado has both the highest per-capita use of medical marijuana and one of the most regulated medical marijuana systems.

In this debate session, we welcome two investigators from Colorado to debate medical marijuana. The presenters will first consider if marijuana should remain a Schedule I substance or be rescheduled to allow investigators to better study its risks and benefits as a Schedule II substance. Second, the presenters will discuss if physicians should prescribe medical marijuana in a similar manner to other prescription medications, weighing the potential benefits and risks of a medication, as well as what it means for a physician to recommend marijuana compared with prescribing marijuana. Next, the presenters will discuss pharmacists dispensing medical marijuana dispensing, including recent examples of laws enabling this role. Lastly, the presenters will speculate on the future use of marijuana as a medicine.

Upon conclusion of the program, the participant should be able to describe the historical and current legal status of marijuana, evaluate the medical benefits and risks associated with medical marijuana, identify known psychiatric consequences and drug interactions with marijuana use, discuss the role of pharmacists when patients choose to use medical marijuana, and predict the future of medical marijuana in the United States.

learn more

2.0
Registration closed.
06/12/2014 - 04/29/2017 Gambling Addiction ACPE
This session is intended to give the audience a primer on gambling addiction. The presentation will focus on reviewing several ...[more]

This session is intended to give the audience a primer on gambling addiction. The presentation will focus on reviewing several aspects of gambling addiction including epidemiology and pathophysiology of gambling addiction and the DSM-5 criteria of gambling addiction. The presentation will also focus reviewing both the nonpharmacologic and pharmacological treatments of gambling disorders. The presentation will incorporate audience participation and response throughout the presentation. Gambling disorders present in a variety of treatment settings, especially in inpatient psychiatric hospitals and substance abuse treatment centers, highlighting the need for pharmacists to become familiar with this disabling but, often hidden, addictive disorder.

learn more

1.0
Registration closed.
06/12/2014 - 04/29/2017 Improving Naloxone Access to Promote Opioid Safety ACPE
Public health in this country has been threatened by drug overdose deaths which often involve opioid analgesics. This presentation ...[more]

Public health in this country has been threatened by drug overdose deaths which often involve opioid analgesics. This presentation will discuss the current status of opioid related mortality and practical approaches health care providers can take to minimize overdose deaths and facilitate access to the opioid antidote naloxone.

learn more

1.0
Registration closed.
06/12/2014 - 04/28/2017 Managing Drug Shortages in the Provision of Electroconvulsive Therapy ACPE
Drug shortages are becoming ever more common the United States, with the number of drug shortages nearly tripling between 2005 and ...[more]

Drug shortages are becoming ever more common the United States, with the number of drug shortages nearly tripling between 2005 and 2010. For the period from January through October 2011, the Food and Drug Administration reported 220 drug shortages, most commonly involving generic injectable medications.  Shortages of injectable medications used during electroconvulsive therapy (ECT) are of particular concern due to the limited available alternatives. This was evidenced when methohexital, considered the “gold standard” anesthetic for ECT procedures, was on national shortage from 2002-2003.

The impact of medication shortages on the availability of ECT poses a significant challenge to clinicians. Because ECT is a short procedure, standard practice is to use very short-acting anesthetic and neuromuscular blocking agents. Potential alternative anesthetic and neuromuscular blocking agents may have substantial clinical impact due to differential pharmacokinetic and/or pharmacodynamic properties. Amy M. VandenBerg, PharmD, BCPP, will discuss the pharmacology and evidence-based alternatives for induction agents, neuromuscular blockers, and adjunctive agents for ECT to enable pharmacists and other clinicians to make the best choices and recommendations in the setting of national drug shortages.

learn more

1.0
Registration closed.
06/12/2014 - 04/30/2017 Mood Disorders as Metabolic Inflammatory Disorders: Implications for Disease Modeling, Clinical Care and Future Treatment and Prevention ACPE
During the past decade, there has been renewed interest in the role of inflammation in the pathogenesis, phenomenology, ...[more]

During the past decade, there has been renewed interest in the role of inflammation in the pathogenesis, phenomenology, comorbidity, and treatment of mood disorders. The novel insights from both basic and clinical research provide empirical evidence to support the hypothesis that inflammation may also account for neuroprogression and cognitive impairment in individuals with mood disorders. Taken together, these observations provide the rationale for evaluating "anti-inflammatory treatments" for individuals with mood disorders. This presentation will review results from recently completed trials indicating that anti-inflammatory agents are possibly effective treatment avenues for adults with mood disorders.

learn more

1.0 $15.00
06/12/2014 - 04/29/2017 Multiple Sclerosis-The Role of New Agents ACPE
Three new oral agents, fingolimod, teriflunomide, and dimethyl fumarate, have been approved for multiple sclerosis (MS) in the past ...[more]

Three new oral agents, fingolimod, teriflunomide, and dimethyl fumarate, have been approved for multiple sclerosis (MS) in the past four years. They carry unique mechanisms of action and adverse effects. This session reviews the efficacy and safety of these agents in detail, then discusses their role in the current landscape of MS therapy. All available agents will be compared with regard to route of administration, efficacy, adverse effects, and costs. Different treatment strategies, including sequential monotherapy, induction and maintenance, and combination therapy will also be discussed.

learn more

1.0
Registration closed.
06/12/2014 - 04/28/2017 Negative Symptoms in Schizophrenia: A Place for Oxytocin? ACPE
Oxytocin, a naturally-occurring hormone, has been of increasing interest to clinical researchers for possible effects on symptoms ...[more]

Oxytocin, a naturally-occurring hormone, has been of increasing interest to clinical researchers for possible effects on symptoms of multiple CNS disorders, including anxiety disorders, autism-spectrum, mood disorders, addiction, and schizophrenia. Within the last four years, several studies have reported effects of adjunctive oxytocin administration on persons with schizophrenia treated with antipsychotics. Negative symptoms of schizophrenia are particularly challenging to treat, and there is a great need for interventions targeting this symptom domain. This talk will briefly review negative symptoms of schizophrenia and the efficacy of available antipsychotic medications in treating these symptoms. The focus of this talk will then shift to the safety, mechanism of action, and current body of evidence surrounding the use of adjunctive oxytocin for the treatment of negative symptoms of schizophrenia.

learn more

1.0
Registration closed.
06/12/2014 - 04/29/2017 Obesity: Understanding the Role of Leptin and Potential Treatment Targets ACPE
Obesity in the US is prevalent and people with severe mental illness are at even greater risk than the general population for ...[more]

Obesity in the US is prevalent and people with severe mental illness are at even greater risk than the general population for developing obesity or obesity-related health disorders. Numerous lines of evidence have suggested that energy balance in animals and humans is tightly controlled. With the identification of leptin and its receptors by Dr. Friedman and his group, two of the molecular components of a system that maintains constant weight have been identified. Leptin is a hormone secreted by the adipose (fat) tissue in proportion to its mass that in turn modulates food intake relative to energy expenditure. Increased fat mass increases leptin levels, which in turn reduces body weight; decreased fat mass leads to a decrease in leptin levels and an increase in body weight. By this mechanism, weight is maintained within a relatively narrow range. Defects in the leptin gene are associated with severe obesity in animals and in humans. Leptin acts on sets of neurons in brain centers that control energy balance. Leptin also plays a general role in regulating many of the physiologic responses that are observed with changes in nutritional state, with clear effects on female reproduction, immune function, and the function of many other hormones, including insulin.

In his talk, Dr. Friedman will discuss the impact of obe­sity in society and its prevalence among patients with mental illness. He will examine the pathophysiologic basis for obesity, the emerging role of understanding the role of leptin in obesity and feeding behavior, and touch upon treatment targets for obesity based on dysregulations in hormone function.

learn more

1.0
Registration closed.
06/12/2014 - 04/29/2017 Prevention of Migraine Headaches: When to Use Botulinum Toxins ACPE
Migraine ranks as one of the world’s most prevalent illnesses, causing significant amounts of debilitation, pain, and lost ...[more]

Migraine ranks as one of the world’s most prevalent illnesses, causing significant amounts of debilitation, pain, and lost productivity. Yet patients and clinicians tend to underestimate migraine’s pervasiveness and impact. Treatment of migraine remains less than optimal. In select suffers episodic migraine can evolve to a chronic state, where the patients endures a headache on the majority of the days of the month. Overuse of medications, particularly narcotics and butalbital, have been implicated as a chief cause for the development of chronic migraine.  

This program will review migraine’s epidemiology, discuss evidence-based treatment recommendations, highlight the risks of narcotic and butalbital medications, and feature opportunities for pharmacists to improve care. The session will conclude by reviewing onabotulinumtoxinA, the only FDA-approved treatment for chronic migraine.

learn more

1.0
Registration closed.
06/12/2014 - 04/27/2017 Rational or Irrational: Polypharmacy in Psychiatry ACPE
Polypharmacy with psychiatric drugs is common. Combinations of antipsychotic drugs upon hospital discharge have come under scrutiny ...[more]

Polypharmacy with psychiatric drugs is common. Combinations of antipsychotic drugs upon hospital discharge have come under scrutiny by The Joint Commission. The evidence base for the use of combined antipsychotic medications and combined antidepressant medications is limited. Available evidence will be presented and evaluated in order to identify situations where combination therapy may be rationally applied to patient care. Hospital-Based Inpatient Psychiatric Service (HBIPS) measures regarding antipsychotic polypharmacy will be described and potential roles for pharmacists in complying with these measures will be discussed. The potential risks of antipsychotic polypharmacy have been identified and include increased risk of endocrinologic disturbances such as hyperprolactinemia as well as a possible increase in all-cause mortality associated with combinations of antipsychotics. Evidence supporting combination therapy with antipsychotic medications is minimal, although there may be a role for some combinations including clozapine. Antidepressant polypharmacy, despite theoretical justification based on hypothesized mechanisms of action of various antidepressants, has not been demonstrated to be of benefit, although most trials have been small and uncontrolled. While initial studies appeared to identify a potential advantage to initiation of treatment with combined antidepressants, this was not confirmed in more extensive studies (CO-MED). There is a potential for genetic phenotyping to assist in optimization of monotherapy as well as to explain apparent successes with polypharmacy that are actually related to drug-drug interaction at metabolizing enzymes.

learn more

1.0
Registration closed.
06/12/2014 - 04/29/2017 The Pharmacist’s Role in a Transformed Health Care System: Opportunities for Mental Health ACPE
Pharmacy is undergoing one of the most transformative and fundamental shifts as a profession. With  the healthcare delivery ...[more]

Pharmacy is undergoing one of the most transformative and fundamental shifts as a profession. With  the healthcare delivery and payment system move to reward coordination of care and improved outcomes, the opportunity to effectively manage and recommend the most appropriate and safe medications for individual patients (as the “experts in medication”)can establish the value proposition for comprehensive medication management services delivered by pharmacists.

learn more

1.0
Registration closed.
06/12/2014 - 04/28/2017 Treatment Resistant Depression and the Role of NMDA Antagonists ACPE
The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, a dissociative anesthetic agent with potential abuse ...[more]

The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, a dissociative anesthetic agent with potential abuse liability, has shown rapid antidepressant effects, but small sample sizes and inadequate control conditions in prior studies have precluded a definitive conclusion. This talk will summarize recent work related to ketamine's antidepressant properties and will discuss hypotheses regarding its putative mechanism of action in depression.

learn more

1.0
Registration closed.
06/12/2014 - 04/29/2017 Violence and Mental Illness: A Public Dilemma ACPE
Following the December, 2012, massacre of schoolchildren in Newtown, Connecticut, competing conversations about mental illness and ...[more]

Following the December, 2012, massacre of schoolchildren in Newtown, Connecticut, competing conversations about mental illness and violence, safety and civil rights, prediction and prevention, policy and practice collided in the public square. What can scientific evidence contribute in such a moment? What is known about the link between psychopathology and violent behavior? Are clinicians able to “predict” violence in their patients? How effective is psychiatric treatment in reducing violence risk in people with serious mental illnesses? The presenter will bring current evidence to bear on these questions and discuss implications for clinicians and mental health stakeholders.

learn more

1.0
Registration closed.
05/28/2014 - 04/28/2017 Eating Disorders: What’s on the Menu for Pharmacologic Treatment? ACPE
Weight has been a significant focus in the medical and lay media, both in perception of body image and impact on the overall health ...[more]

Weight has been a significant focus in the medical and lay media, both in perception of body image and impact on the overall health and well-being of patients. Eating disorders encompass a number of disorders such as anorexia nervosa, bulimia nervosa, and binge eating that result from an individual's actions to control or adjust their body weight or shape. Since treatment of these conditions often relies less on pharmacologic management than on other treatment modalities, pharmacists may not be up-to-date on the appropriate management of patients with eating disorders.

learn more

1.0
Registration closed.
05/16/2014 - 05/16/2017 Developing a First-Line Post-Traumatic Stress Disorder Treatment Plan: PTSD Due to a Motor Vehicle Accident ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of post-traumatic stress disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated post-traumatic stress disorder. The course will require 1.5 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5 $15.00
05/16/2014 - 05/16/2017 Developing a First-Line Social Anxiety Disorder Treatment Plan: The Case of the Embarrassed Medical Student ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of social anxiety disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated social anxiety disorder. The course will require 1.5 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5 $15.00
04/08/2014 - 04/08/2017 Developing a First-Line Panic Disorder Treatment Plan: A Case of New Onset Panic Disorder ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of panic disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated panic disorder. The course will require 1.5 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5
Registration closed.
02/03/2014 - 07/23/2014 2014-2015 Psychiatric Pharmacotherapy Review Course BCPP Recertification Credit Edition ACPE 2.0
Registration closed.
02/03/2014 - 02/03/2016 2014-2015 Psychiatric Pharmacotherapy Review Course - No Credit
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Anxiety Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of anxiety disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of anxiety disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Biostatistics and Research Design in Psychiatry ACPE ACCME
This self-study course is designed to assist the learner in selecting and evaluating sources for biomedical information appropriate ...[more]

This self-study course is designed to assist the learner in selecting and evaluating sources for biomedical information appropriate for psychiatric pharmacy practice. Content includes a comprehensive outline and author presentation with focus on how to critically evaluate a study with regard to design and methodology, sources of bias, and significance and applicability of findings.

learn more

1.5
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Bipolar Disorder ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of bipolar disorder. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of bipolar disorder. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Depression ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of depression. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of depression. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Economic and Outcome Studies in Psychiatry ACPE ACCME
This self-study course focuses on understanding and interpreting pharmacoeconomic studies. Using a comprehensive outline and ...[more]

This self-study course focuses on understanding and interpreting pharmacoeconomic studies. Using a comprehensive outline and complimentary author presentation, learners will understand the difference between efficacy and effectiveness studies and the different types of pharmacoeconomic studies. Focus will be placed on the different types of outcomes, the features of decision and sensitivity analysis, the key features of meta-analyses and the common statistical analyses included in a meta-analysis.

learn more

1.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Neurologic Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of neurologic disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of neurologic disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Pediatric Psychiatric Issues or Disorders Usually First Diagnosed in Childhood or Adolescence ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of pediatric related diseases. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of pediatric related diseases. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Personality Disorders and Eating Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of personality disorders and eating disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of personality disorders and eating disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Psychiatric Issues in the Elderly ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of elderly psychiatric issues. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of elderly psychiatric issues. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Regulatory Issues in Pharmacy Practice ACPE ACCME
This self-study course focuses on understanding compliance requirement standards established by national accrediting and regulatory ...[more]

This self-study course focuses on understanding compliance requirement standards established by national accrediting and regulatory agencies. Content includes a comprehensive outline and author presentation on topics such as Pharmacy and Therapeutics Committee, formulary management, Medication Use Evaluation, and performance improvement cycles are described. The Joint Commission standards, State Operations Manual F-tags and the roles of IRBs and various governmental agencies are also addressed in this course.

learn more

1.5
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Schizophrenia and Movement Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of schizophrenia and movement disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of schizophrenia and movement disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

2.0
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Sleep Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of sleep disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of sleep disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5
Registration closed.
02/03/2014 - 02/03/2016 Psychiatric Pharmacotherapy Review Course-Substance Use Disorders ACPE ACCME
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the ...[more]

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of substance use disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of substance use disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

learn more

1.5
Registration closed.
01/21/2014 - 01/21/2016 Pharmacotherapy for Psychiatric Disorders in Primary Care ACPE
Patients with mental health conditions are more commonly seen in primary care than in other health care settings, but as much as ...[more]

Patients with mental health conditions are more commonly seen in primary care than in other health care settings, but as much as half of their mental health conditions go undiagnosed. Most primary care providers (PCPs: physicians, nurse practitioners, physician’s assistants, pharmacists) are not fully trained to diagnose or treat mental health conditions. Mental health issues go undiagnosed or inadequately treated, and inappropriate psychotropic drugs may be prescribed with little follow-up.

learn more

1.5
Registration closed.
12/23/2013 - 12/23/2016 Developing a First-Line Bipolar Treatment Plan: The Case of the Untamed Soul ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of bipolar disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated bipolar disorder. The course will require 2 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case. 

learn more

2.0
Registration closed.
12/23/2013 - 12/23/2016 Developing a First-Line Generalized Anxiety Disorder Treatment Plan: The Case of the Worrying Waitress ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of generalized anxiety disorder. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated generalized anxiety disorder. The course will require 1.25 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.5
Registration closed.
12/23/2013 - 12/23/2016 Developing a First-Line Schizophrenia Treatment Plan: A Case of New Onset Schizophrenia ACPE
This course is designed to provide participants with a review minimal experience of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with a review minimal experience of evidenced-based first line strategies for the treatment of schizophrenia. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated schizophrenia. The course will require 2 hours for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case. 

learn more

2.0
Registration closed.
12/23/2013 - 12/23/2016 Implementing Second- and Third-Line Bipolar Therapies: The Case of the TV Critic ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of bipolar disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with bipolar disorder will also be emphasized.

learn more

2.0
Registration closed.
12/23/2013 - 12/23/2016 Implementing Second- and Third-Line Depression Therapies: The Case of the Sad Mechanic ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of depression. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with depression will also be emphasized.

learn more

2.0
Registration closed.
12/23/2013 - 12/23/2016 Implementing Second- and Third-Line Generalized Anxiety Therapies: The Case of the Irritable Golfer ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of generalized anxiety disorder. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with generalized anxiety disorder will also be emphasized.

learn more

1.5
Registration closed.
12/23/2013 - 12/23/2016 Implementing Second- and Third-Line Schizophrenia Therapies: A Case of Treatment Resistance, Dystonia and Tardive Dyskinesia ACPE
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line ...[more]

This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of schizophrenia. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with schizophrenia will also be emphasized.

learn more

2.0
Registration closed.
12/06/2013 - 12/06/2016 Conducting Scientific Peer Review
This not-for-credit course provides an introductory look at conducting peer review. Learn how to formulate productive comments, and ...[more]

This not-for-credit course provides an introductory look at conducting peer review. Learn how to formulate productive comments, and take a look at the actual review process used by the Mental Health Clinician in 2013.

learn more

Registration closed.
11/15/2013 - 11/15/2016 Down in the Dumps: Developing a Depression Treatment Plan ACPE
This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the ...[more]

This course is designed to provide participants with minimal experience a review of evidenced-based first line strategies for the treatment of depression. The goal is that participants will be able to formulate an effective and safe drug therapy plan that can be implemented in a patient with uncomplicated depression. The course will require 1 hour for completion and will consist of review of a recommended reading and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case.

learn more

1.0
Registration closed.
09/04/2013 - 09/04/2016 Comprehensive Medication Management: The Path to Payment for Patient-Care Services
In September of 2012, the College of Psychiatric and Neurologic Pharmacists adopted Comprehensive Medication Management (CMM) as ...[more]

In September of 2012, the College of Psychiatric and Neurologic Pharmacists adopted Comprehensive Medication Management (CMM) as the gold standard of practice for clinical pharmacists. But what is CMM and how does one go about implementing it? Additionally, how do we document and prove our value within this model? Lastly, can we get paid for these services? These are the questions we plan to answer through a webinar series starting in October 2013.

learn more

04/24/2013 - 04/24/2016 Leveraging mHealth to Enhance Patient Engagement and Outcomes ACPE
This session will provide an overview of the emerging area of mobile health (mHealth) relative to the profession of pharmacy. Areas ...[more]

This session will provide an overview of the emerging area of mobile health (mHealth) relative to the profession of pharmacy. Areas of focus will include the potential roles of mHealth in improving patient engagement and outcomes, with a special emphasis on mental health. Evidence and theory supporting mobile devices and applications (apps) used to facilitate behavior change will be discussed. Specific apps used for mental health (e.g., depression) will be profiled. Strategies to employ mHealth apps and tools will be provided, including targeting specific patient populations and practice settings. Finally, categories of hurdles to be navigated with mHealth endeavors will be delineated, including legal, societal, and technological.

learn more

1.0
Registration closed.
04/24/2013 - 04/24/2016 Transforming 300 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Disease ACPE
Wednesday, April 24, 2013, 10:00-11:00 AM There is an urgent need to translate genome-era discoveries into clinical utility, but ...[more]

Wednesday, April 24, 2013, 10:00-11:00 AM

There is an urgent need to translate genome-era discoveries into clinical utility, but the difficulties in making bench-to-bedside translations have been well described. Large funding initiatives have led to the systematic measurements of many relevant aspects of biology, from transcription and translation to the workings of pharmacology. But very little of this data is actually ever used beyond the handful of papers that introduce these data to the world.

The nascent field of translational bioinformatics may bridge these opportunities. Dr. Butte’s lab at Stanford builds and applies tools that convert more than 300 billion points of molecular, clinical, and epidemiological data -- measured by researchers and clinicians over the past decade -- into diagnostics, therapeutics, and new insights into disease. Dr. Butte, a bioinformatician and pediatric endocrinologist, will highlight his lab’s work on using publicly-available molecular measurements to find new uses for drugs including drug repositioning for inflammatory bowel disease and discovering new treatable inflammatory mechanisms of disease in type 2 diabetes, and how patients presenting with whole genome sequences can be evaluated. As the new Principal Investigator of ImmPort, the long-term, sustainable data warehouse of immunological data generated by NIAID-funded investigators, Dr. Butte will highlight how molecular and clinical trials data can be shared and reused to drive scientific discovery.

View a 14 minute clip of Dr. Butte at TEDMED 2012

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 A Review of Toxidromes: Recognition and Management ACPE
Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are uncommon but potentially life-threatening adverse reactions ...[more]

Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are uncommon but potentially life-threatening adverse reactions associated with psychotropic medications. Polypharmacy and the similar presentation of SS and NMS make diagnosis of the two syndromes problematic. The majority of available literature on SS and NMS consists of case reports, case-control studies, and retrospective reviews. In addition, diagnostic criteria have been developed to aid in the diagnosis and management of SS and NMS. SS presents as mental status changes, autonomic nervous system disturbances, neurologic manifestations, and hyperthermia. Similarly, NMS presents as muscle rigidity, hyperpyrexia, mental status changes, and autonomic instability. However, the clinical laboratory profile of elevations in creatine kinase, liver function tests (lactate dehydrogenase, aspartate transaminase), and white blood cell count, coupled with a low serum iron level, distinguishes NMS from SS among patients taking neuroleptic and serotonin agonist medications simultaneously. For both SS and NMS, immediate discontinuation of the causative agent is the primary treatment, along with supportive care. For NMS, dantrolene is the most effective evidence-based drug treatment whereas there are no evidence-based drug treatments for SS but theoretically the serotonin-2A antagonist is a pharmacological rational antidote. A 2-week washout of neuroleptic medication minimizes the chance of recurrence among patients who require rechallenge with neuroleptic medication.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Academic Detailing: Demonstrating Clinician Effective Educational Techniques ACPE
Background: As part of the major initiative to Improve Veterans Mental Health, Pharmacy Benefits Management Services (PBM) and ...[more]

Background: As part of the major initiative to Improve Veterans Mental Health, Pharmacy Benefits Management Services (PBM) and Mental Health Services (MHS) in VA Central Office selected VISNs 21 and 22 to pilot the use of Academic Detailing (AD) within mental health. Academic Detailing (AD), a service that provides educational outreach visits, has been effective in changing prescribing habits in a variety of practice settings.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Academic Detailing: Using Clinical Evidence to Improve Care ACPE
Clinicians practicing evidence-based medicine strive to use research results to guide their clinical decision making so that they ...[more]

Clinicians practicing evidence-based medicine strive to use research results to guide their clinical decision making so that they can take the best possible care of their patients. However, implementing evidence-based practice can be challenging for clinicians. The volume of medical research is vast and growing rapidly, making it impractical for busy front-line clinicians to keep up with new findings. Furthermore, clinicians struggle to identify which research studies are of the highest quality and should be incorporated into practice. Many clinicians feel overwhelmed by these demands and negative perceptions of evidence-based medicine are common. Academic detailing is an educational outreach technique that brings the best clinical evidence to front-line clinicians in a usable format to support improved care. By adapting the principles of social marketing, originally used by sales representatives for pharmaceuticals, academic detailers work with clinicians in one-on-one educational sessions, assessing needs, strengths, and preconceptions so that the messages can be tailored to the individual. Randomized controlled trials have demonstrated that academic detailing can improve the quality of care in multiple settings. In the current era of health care reform, academic detailing interventions are often implemented as a part of multifaceted efforts to improve health care quality.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Cracking Down on Antipsychotic Use in the Elderly: The Risks, the Recommendations, and Treatment ACPE
This session will provide a comprehensive overview for attendees on the evidence base behind concerns with the use of ...[more]

This session will provide a comprehensive overview for attendees on the evidence base behind concerns with the use of antipsychotics in older persons with dementia. These safety concerns as well as public advocacy led to the Centers for Medicare and Medicaid Services taking action to improve the behavioral health and approach to caring for residents in America’s Nursing Homes. There have multiple aspects to reducing inappropriate antipsychotic use through this national initiative, which will be discussed. To round out this session, the presenter will provide evidence base on alternative approaches to antipsychotics as well as take home points that can be implemented within your clinical settings.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Deep Brain Stimulation for Movement Disorders: A Primer ACPE
Deep brain stimulation (DBS) or neuromodulation is the most commonly performed surgical procedure for movement disorders. Devices ...[more]

Deep brain stimulation (DBS) or neuromodulation is the most commonly performed surgical procedure for movement disorders. Devices for DBS are FDA-approved for the management of essential tremor, Parkinson’s disease (PD), and dystonia. The former two are the most frequent indications for DBS neuromodulation. In the case of essential tremor, DBS of the thalamus is most appropriate for individuals who are refractory to pharmacotherapy. For PD, DBS of the subthalamic nucleus or globus pallidus interna is most appropriate for ambulatory individuals with significant motor fluctuations and dyskinesias despite best medical treatment. This interactive and case-based session will provide a primer on DBS for movement disorders with an emphasis on essential tremor and PD. Topics will include device overview, neuroanatomy, mechanism of action, efficacy, safety, patient selection, use of concurrent pharmacotherapy, and DBS programming.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Pearls: Implementing Comprehensive Medication Management for Patients with Mental Illness ACPE
With the continued introduction of the Affordable Care Act, states continue to implement patient-centered medical homes and ...[more]

With the continued introduction of the Affordable Care Act, states continue to implement patient-centered medical homes and health-insurance exchanges. Numerous organizations are working on implementing comprehensive medication management (CMM) in the PCMH but there are numerous challenges in the process of integration. Pharmacists can help with this integration through implementing CMM involving partnering with patients and other health-care providers to ensure that outcomes are improved and costs reduced. This session will provide several real-life examples of initial efforts at integration. Three presenters will provide examples of how they have incorporated CMM into their practice setting and tips for overcoming barriers to do so.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Rewriting the Psychiatric Bible: The DSM-5 and its Implications ACPE
In May 2013, the American Psychiatric Association will release the fifth edition of the Diagnostic and Statistical Manual of Mental ...[more]

In May 2013, the American Psychiatric Association will release the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, DSM-5. The DSM-5 is so critical to the contemporary practice of psychiatry that it is often called the ‘psychiatric bible.’ While alternative diagnostic manuals exist, the DSM-5 is the clear standard, in both domestic and international psychiatry. In order to prepare for the release of DSM-5, practitioners need to review the history of the DSM, the rationale behind this revision, the categorical and organizational changes in DSM-5, and how DSM-5 will alter clinical practice. We will review these topics together, considering the strengths and limitations of DSM-5, alternative diagnostic systems, and how each version of the DSM corresponds to its historical moment.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 The Recognition and Management of Delirium in the Critically Ill ACPE
Delirium is frequently observed in critically ill patients and is associated with deleterious outcomes in the hospital and after ...[more]

Delirium is frequently observed in critically ill patients and is associated with deleterious outcomes in the hospital and after discharge, including long-term cognitive dysfunction. Screening for the presence of delirium with a validated tool like the Confusion Assessment Method (CAM) – ICU or the Intensive Care Delirium Screening Checklist (ICDSC) should occur frequently to detect delirium in an effort to reduce the duration. Non-pharmacologic interventions may prevent the occurrence of delirium and must be routinely considered. Substituting the use of traditional sedatives with dexmedetomidine and early ambulation have been shown in large studies to reduce the occurrence and/or duration of delirium. No data support the use of haloperidol for treatment. Limited studies reflect the safety of atypical antipsychotic agents for treatment but lack clear improvement in delirium-related outcomes. The pharmacist is ideally situated to aid in the recognition of delirium, institute pharmacologic and non-pharmacologic prevention mechanisms, minimize sedation, and recommend appropriate treatment including the discontinuation of therapy. Ultimately, the best treatment is prevention which involves a multi-professional multimodal approach. The goals of this session for the attendee are 1) describe the signs and symptoms of delirium and delineate two tools used to identify delirium in critically ill patients; 2) explain the clinical significance and associated outcomes of delirium in critically ill patients; 3) identify risk factors for delirium in critically ill patients; and 4) develop prevention and treatment plans for delirium in the critically ill patient.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Trends in Synthetic Drugs of Abuse ACPE
Synthetic drugs are increasingly abused and are easily available at in retail stores and online. In many cases there are minimal ...[more]

Synthetic drugs are increasingly abused and are easily available at in retail stores and online. In many cases there are minimal restrictions on purchase, and owing to their legal status are often assumed to be safe. Newer synthetic drugs are responsible for adverse events, ER visits and calls to poison control centers. These drugs are difficult to legislate, as restrictions often result in manufacturers making minimal alterations that result in new, legal versions. Omar Manejwala, MD, MBA, FAPA, will discuss the pharmacological aspects of newer synthetic drugs of abuse, their clinical effects, and the role that pharmacists can play in synthetic drug use prevention and early intervention, including advocacy for policy change.

learn more

1.0
Registration closed.
04/23/2013 - 04/23/2016 Update in the Management of Huntington's Disease ACPE
Huntington's Disease (HD) is a progressive neurological disorder, first described by George Huntington in 1872, characterized ...[more]

Huntington's Disease (HD) is a progressive neurological disorder, first described by George Huntington in 1872, characterized by chorea, as well as cognitive and behavioral dysfunction.  The United States incident rates of HD are approximately 4 to 7 out of 100,000. HD is inherited in an autosomal dominant pattern, and genetic confirmation is done by examining the number of CAG repeats on chromosome 4. The diagnosis of HD can also be clinical. Although there is no cure for HD, current therapies are generally directed against chorea and psychiatric manifestation of the disease. Current therapies to treat chorea involve both dopamine depleting agents and dopamine antagonists. Pharmacotherapy for the psychiatric manifestations of HD is often individualized since clinical presentation will vary from patient to patient.

learn more

1.0
Registration closed.
04/22/2013 - 04/22/2016 Beyond Psychopharmacology: The Role of Cognitive Behavioral Therapy for Obsessive- Compulsive Disorder in Children and Adolescents ACPE
Many studies have documented the significant functional impairment and comorbidity associated with obsessive compulsive disorder ...[more]

Many studies have documented the significant functional impairment and comorbidity associated with obsessive compulsive disorder (OCD) in children and adolescents. Fortunately, cognitive-behavioral therapy (CBT) protocols have been developed and tested that reduce OCD and related symptoms and improve functioning. The epidemiology, clinical presentation, and consequences of untreated OCD in children and adolescents will be described. The efficacy of CBT compared to pharmacologic treatments for OCD in children and adolescents will be discussed along with results of the Pediatric OCD Treatment Studies (POTS I and POTS II). The treatment of very young children using family-based CBT will be addressed. The components of CBT and when to use this treatment approach either alone or in combination with pharmacotherapy, and when to use alternate strategies in children and adolescents will be presented.

learn more

1.0
Registration closed.
04/22/2013 - 04/22/2016 New and Emerging Data on the Use of Different Therapies in the Treatment of PTSD ACPE
Posttraumatic Stress Disorder (PTSD) may occur after exposure to severe psychological trauma such as combat, assault, or childhood ...[more]

Posttraumatic Stress Disorder (PTSD) may occur after exposure to severe psychological trauma such as combat, assault, or childhood abuse. The disorder is highly prevalent in the U.S., e.g.  Epidemiologic Catchment Area data suggest a prevalence of 7.8%. PTSD involves characteristic symptom clusters including re-experiencing of the trauma through intrusive memories, nightmares, or other symptoms; avoidance of reminders of the trauma; emotional numbing; and symptoms of increased arousal. There is also extensive comorbidity associated with PTSD including mood disorders, alcohol and substance dependence, psychosis, and other psychiatric diagnoses. Chronic PTSD may also increase risk for medical disorders such as cardiovascular disease. Significant and at times debilitating functional impairment may occur in patients suffering from PTSD. Treatment approaches include psychotherapy, other psychosocial interventions, and medications. The complexity of symptoms as well as the extensive comorbidity in PTSD represents a major challenge for treatment. Two antidepressants, sertraline and paroxetine, are FDA-approved for PTSD. Many patients do not have an adequate response to these medications, or to psychotherapy, therefore many other approaches have been studied. This presentation will review the basic phenomena and epidemiology of PTSD, give a brief overview of neurobiological alterations in PTSD, review medication approaches as well as combined psychotherapy and medication, and review a complex case example.

learn more

1.0
Registration closed.
04/22/2013 - 04/22/2016 Pharmacogenetics of Bipolar Disorder: Clinical Application and Drug Response ACPE
Bipolar Disorder is a common, life threatening psychiatric illness with a recurring course and lifetime prevalence of attempted ...[more]

Bipolar Disorder is a common, life threatening psychiatric illness with a recurring course and lifetime prevalence of attempted suicide of 17-24%. Diagnosis can be difficult due to shared symptomatology with other diagnoses and clinically comorbid psychiatric disease states. Given the wide, individual variation in medication response, there is a great need for personalized medicine and pharmacogenomic research in this patient population.  Most studies to date have focused largely on lithium and suggest the idea that different medication responses may reflect different disease mechanisms. In his talk, Dr. Kelsoe will discuss the use of lithium in bipolar disorder, the clinical need for pharmacogenetics of lithium response, a review of genomic methods that are used to identify genes influencing drug response, and will describe the value of pharmacogenetics in better understanding the mechanism of bipolar disorder.

learn more

1.0
Registration closed.
04/22/2013 - 04/22/2016 PTSD Related Sleep Disorders ACPE
Approximately 70% of patients with PTSD suffer from disrupted sleep patterns, including nightmares and distressed awakenings. These ...[more]

Approximately 70% of patients with PTSD suffer from disrupted sleep patterns, including nightmares and distressed awakenings. These symptoms are highly disturbing and have a profound negative effect on more than just an individual’s sleep; they likely exacerbate daytime hypervigilance, irritability and anger thresholds, avoidance symptoms, affect physical health and contribute to decreased quality of life. Norepinephrine plays a role in the pathyophysiology of PTSD and it is thought that the increase in the central nervous system responsiveness to norepinephrine contributes to the disruption of normal rapid eye movement sleep, in turn contributing to trauma related nightmares and distressed awakenings. Prazosin, a lipid-soluble alpha-1 adrenoreceptor antagonist, can be used to decrease the responsiveness to norepinephrine in the central nervous system thus returning the patient to a normal sleep pattern. This presentation will review the literature that supports the use of prazosin for the treatment of PTSD-related nightmares. The effects on sleep disturbance of other psychotropic drugs commonly prescribed for PTSD also will be reviewed.

learn more

1.0
Registration closed.
04/22/2013 - 04/22/2016 Schizoaffective Disorder: Clearing the Fog of Treatment Options ACPE
Schizoaffective disorder (SZA), since its introduction 80 years ago, has raised considerable controversy regarding its distinction ...[more]

Schizoaffective disorder (SZA), since its introduction 80 years ago, has raised considerable controversy regarding its distinction from schizophrenia and mood disorders, as well as its validity as an independent diagnostic category. DSM-IV-TR allows diagnosis of SZA based upon a current episode of illness, leading to its common use in acute care settings.  The proposed changes in DSM-5 for SZA will require consideration of the lifetime of illness, which will significantly reduce the prevalence of SZA. The most consistent findings in SZA literature are that SZA is often used incorrectly by clinicians, and SZA has very low diagnostic reliability over time. Increasing evidence that schizophrenia and bipolar disorder share genetic mechanisms creates further uncertainty about the diagnosis of SZA. An evidence-based approach to the treatment of SZA is not feasible since so few studies have been done to specifically evaluate antipsychotics, mood stabilizers, antidepressants, and their combinations.  Rather, treatment must rely on the evidence base established for the treatment of schizophrenia, bipolar disorder, and depression with treatment decisions guided by presenting symptoms. Because a diagnosis of SZA requires meeting criteria for schizophrenia, antipsychotic drugs are the primary treatment for SZA. Recommendations for acute treatment of SZA bipolar type is an antipsychotic drug, with a mood stabilizer added for depressive symptoms, while maintenance treatment is an atypical antipsychotic alone or in combination with a mood stabilizer. Treatment of SZA depressive type has virtually no literature basis, but an antipsychotic plus antidepressant, or antipsychotic plus a mood stabilizer is recommended.

learn more

1.0
Registration closed.
04/21/2013 - 04/21/2016 Expecting the Unexpected: Treatment of Opioid Dependence in Pregnancy ACPE
Opioid use in pregnancy includes the use of heroin and the misuse or abuse of prescription opioid medications. Untreated opioid ...[more]

Opioid use in pregnancy includes the use of heroin and the misuse or abuse of prescription opioid medications. Untreated opioid dependence during pregnancy can have devastating consequences to a developing fetus. Methadone maintenance has been the standard of care; however its use can lead to significant neonatal abstinence syndrome. Emerging evidence supports the use of buprenorphine for opioid maintenance during pregnancy. During the intrapartum and postpartum period, special considerations are needed for women who are opioid dependent to ensure appropriate pain management, to prevent relapse and to decrease risk of overdose. Breastfeeding should be encouraged in women who receive buprenorphine or methadone maintenance in the absence of HIV infection or other contraindications. Use of buprenorphine or methadone in pregnancy puts the neonate at risk of abstinence syndrome, which is characterized by hyperactivity of the central and autonomic nervous systems. This educational session will contrast the risks and benefits associated with use of buprenorphine or methadone in pregnant women.

learn more

2.0
Registration closed.
04/21/2013 - 04/21/2016 Safe or Sorry? Antipsychotics for Maintenance Treatment of Bipolar Disorder ACPE
Second-generation antipsychotics (SGAs) have gained popularity as mood-stabilizers and are commonly used in the acute and chronic ...[more]

Second-generation antipsychotics (SGAs) have gained popularity as mood-stabilizers and are commonly used in the acute and chronic management of mania and depression in bipolar disorder. However, the use of SGAs is not without risk. Robust head-to-head comparisons of SGAs and anticonvulsants or lithium are lacking. This presentation will review the current evidence for the use of SGAs in bipolar disorder and compare the risks versus benefits against anticonvulsants and lithium.

learn more

1.0
Registration closed.
10/15/2012 - 10/15/2013 Addressing Negative Symptoms in Schizophrenia: An Examination of Novel Strategies on the Horizon ACPE
Schizophrenia is a chronic, debilitating disorder in which successful long-term management represents a considerable clinical ...[more]

Schizophrenia is a chronic, debilitating disorder in which successful long-term management represents a considerable clinical challenge. However, recent advances in the field are beginning to show promise toward enabling clinicians to render effective, personalized care. This activity will examine diagnostic tools for effective symptom assessment in schizophrenia and evolving theories on the pathogenesis of schizophrenia. The limitations of current antipsychotics will also be discussed, as well as the emergence of novel therapeutics with unique receptor binding profiles with the potential to improve patient outcomes.

The course consists of 4 modules:

  1. Symptom Classification in Schizophrenia
  2. Pathophysiology of Schizophrenia: Neurotransmitters, Receptors and Genetics
  3. Management of Schizophrenia
  4. The Future of Schizophrenia Management

learn more

0.5 - 2.0
Registration closed.
05/02/2012 - 05/01/2015 Medical Marijuana: Magical Cure or Myth? ACPE
One of the most recent clinical controversies is the use of medical marijuana, and there are an increasing number of states in the ...[more]

One of the most recent clinical controversies is the use of medical marijuana, and there are an increasing number of states in the US that have passed legislation to make the use of this agent legal. Although there seems to be high patient demand for medical marijuana, the majority of clinicians may not be aware of the data that is available regarding the safety and efficacy of this treatment.  Dr. Gold will provide a comprehensive overview of available literature that explores both the efficacy and safety data regarding use of medical marijuana.  Although laws vary from state to state, Dr. Gold will also delve into some of the logistics related to the dispensing of this agent. By the end of the session the participant should have a good understanding of both the benefits and risks of the use of medical marijuana so that he or she can apply this to patient care.

learn more

1.0
Registration closed.
05/02/2012 - 05/02/2015 Mental Illness in the Criminal Justice System: Constructing a Comprehensive and Competent Criminal Justice/Mental Health Treatment System ACPE
The deinstitutionalization of psychiatric facilities has been a major factor that has led to the current crisis of the ...[more]

The deinstitutionalization of psychiatric facilities has been a major factor that has led to the current crisis of the criminalization of the mentally ill.  Judge Steven Leifman, a Miami-Dade County Judge who has also served as Special Advisor on Criminal Justice and Mental Health for the Supreme Court of Florida, is responsible for chairing the Court’s Mental Health Subcommittee.  He and his group authored a ground-breaking report entitled, Transforming Florida’s Mental Health System.

During his presentation, Judge Leifman will discuss new and effective strategies that are being developed and employed to transform the mental health system.  He will address ways that providers can assist those with mental health disorders to maneuver the criminal justice system to minimize burden.  Additionally, he will discuss how pharmacists and other health care professionals can get involved in a legislative manner to help transform the mental health system.

Listen to NPR Interview with Judge Leifman

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Drugs in Development: Treating the Core Social and Communication Impairments in Autism ACPE
As evidenced by the ever-increasing research and continued public interest, drug development in autism is a crucial piece in the ...[more]

As evidenced by the ever-increasing research and continued public interest, drug development in autism is a crucial piece in the future of psychopharmacology.  However, due in part to the variability of symptoms in autism, researchers face many roadblocks in finding appropriate pharmacological treatment.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Issues of the Day Metabolic Syndrome and the Psychiatric Patient: Case-Based Application of Newly Released Guidelines ACPE
This program is designed to provide participants with an update on the recommendations from the new Hypertension (JNC 8) and Lipid ...[more]

This program is designed to provide participants with an update on the recommendations from the new Hypertension (JNC 8) and Lipid (ATP IV) guidelines.  The program will consist of a 1 hour lecture and 1 hour case-based discussion by John Tovar, PharmD.  At the end of the program, participants will be able to formulate a safe and effective drug therapy plan that can be implemented in the psychiatric patient.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Metabolic Syndrome and the Psychiatric Patient: A Review of the Newly Released Guidelines ACPE
This program is designed to provide participants with an update on the recommendations from the new Hypertension (JNC 8) and Lipid ...[more]

This program is designed to provide participants with an update on the recommendations from the new Hypertension (JNC 8) and Lipid (ATP IV) guidelines.  The program will consist of a 1 hour lecture and 1 hour case-based discussion by John Tovar, PharmD.  At the end of the program, participants will be able to formulate a safe and effective drug therapy plan that can be implemented in the psychiatric patient.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Neurology Management of Neuropsychiatric Sequelae of Traumatic Brain Injury ACPE
Over 1.5 million Americans sustain a traumatic brain injury (TBI) each year, according to the Centers for Disease Control and ...[more]

Over 1.5 million Americans sustain a traumatic brain injury (TBI) each year, according to the Centers for Disease Control and Prevention (CDC). Approximately 500,000 of these patients die annually, making TBI the third leading injury-related cause of death.  TBI remains a highly complex syndrome of disabilities, often making treatment difficult and controversial.  CPNP is pleased to collaborate with Kimberly A. Arlinghaus, M.D. who will provide a high level overview of TBI in this presentation, including diagnostic features, basic pathophysiology, neuropsychiatric problems, and present guidelines for psychopharmacologic treatment.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Neurology Migraine Treatment in 2012 ACPE
Migraines impact your patient’s daily lives affecting their professional and societal roles. You will hear a discussion on ...[more]

Migraines impact your patient’s daily lives affecting their professional and societal roles. You will hear a discussion on the prevalence and societal impact of migraines and a review of its pathophysiology and tools used for its screening and diagnosis.  Current treatment guidelines for migraines will be highlighted and information on newly approved medications and devices along with products in the pipeline for management of migraines will be discussed. You will leave with tools to quickly assess patients presenting with headaches as a chief complaint.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Personalized Medicine in Depression ACPE
Though depression is one of the most prevalent mental illnesses that psychiatric practitioners will face, response to treatment is ...[more]

Though depression is one of the most prevalent mental illnesses that psychiatric practitioners will face, response to treatment is variable and largely unpredictable.  During this session, Dr. Madhukar Trivedi, MD will identify characteristics which may predict treatment response.  He will also highlight ways to “personalize” the treatment of depression to an individual.  Lastly, Dr. Trivedi will highlight current and future research that focuses on identifying specific predictors of treatment response, such as biomarkers, genes or neuroimaging.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Research Pharmacogenomics for the Practicing Neuropsychiatric Pharmacist ACPE
Genetic factors can result in variance in drug metabolism enzyme function, which is one major mechanism impacting interindividual ...[more]

Genetic factors can result in variance in drug metabolism enzyme function, which is one major mechanism impacting interindividual variability in therapeutic response and side effects to neuropsychiatric medications. This presentation will discuss the promises of pharmacogenetics in psychiatry with the presentation consisting of three components: 1) Results from a pilot study investigating genetic variants in the drug metabolizing enzymes CYP2D6 and CYP2C19 following antidepressants and antipsychotic treatment, 2) Report on the Pharmacogenetics Research Clinic at our CAMH hospital. Patients with a diagnosis of schizophrenia and mood disorders are being enrolled prospectively and genotyped for CYP2D6 and CYP2C19. 3) Major findings in antipsychotic-induced weight gain (AIWG). Unfortunately, AIWG has become a common side-effect with newer antipsychotics and significantly increases morbidity in patients with schizophrenia.

This presentation will highlight our research in this area. Briefly, 1) Our case-reports suggest a potential clinical benefit of CYP genotyping for specific patients, however further validation of CYP2D6 and CYP2C19 testing in prospective, randomized trials is warranted. 2) Our findings suggest that CYP2D6 and CYP2C19 genotyping provides useful information that help physicians to improve pharmacotherapy for individual patients. 3) Our results tentatively suggest novel associations between functionally relevant gene variants in patients treated with antipsychotic medication for schizophrenia.

In this session, implications for treatment in clinical practice will be discussed as well as potential opportunities in drug discovery and drug development, arising from findings in pharmacogenomic studies.

learn more

1.0
Registration closed.
05/01/2012 - 05/01/2015 Research Understanding Genetic Variability and Pharmacogenomic Studies in Psychiatry ACPE
Research in the pharmacogenomics of medications used for neuropsychiatric conditions has identified the potential for using this ...[more]

Research in the pharmacogenomics of medications used for neuropsychiatric conditions has identified the potential for using this technology to personalize treatment by including genetic information. Understanding the biological basis of this technology as well as aspects of research study designs used in pharmacogenomic studies is essential for the clinical pharmacist to understand how to apply this information and its limitations. There are now laboratories that offer pharmacogenomic tests for selected variants in genes that are important for the pharmacokinetics and pharmacodynamics of many medications used in psychiatry practice. This session will provide attendees with information on the technology and studies behind the development of pharmacogenomics tests.

learn more

1.0
Registration closed.
04/30/2012 - 04/30/2015 BCPP Recertification Taking the Ouch Out of Pain Management in Patients with Addiction ACPE
Pharmacists are situated to play a key role in preventing prescription drug misuse and abuse by providing clear information and ...[more]

Pharmacists are situated to play a key role in preventing prescription drug misuse and abuse by providing clear information and advice about how to take a medication appropriately, about the effects the medication may have, and about possible drug interactions. This two hour session will educate pharmacists how to develop collaborative practices with prescribers in order to play an important role in deterring prescription drug abuse by ensuring Universal Precautions are used when controlled substances are prescribed. Patients with current or a past history of substance abuse who are being treated for pain often present therapeutic dilemmas. This session will provide an evidence-based review of the literature to prepare pharmacists to provide valuable guidance in developing a care plan for this special population.

learn more

2.0
Registration closed.
04/30/2012 - 04/30/2015 Finding Common Ground Across the Psychosis Spectrum ACPE
Previously, schizophrenia and bipolar disorder have been classified as two separate diagnoses in the practice of psychiatry.  ...[more]

Previously, schizophrenia and bipolar disorder have been classified as two separate diagnoses in the practice of psychiatry.  However, several findings recently have called into question whether these disorders are etiologically distinct.  Family and twin studies have established that schizophrenia and bipolar disorder are familial and heritable phenotypes with shared genetic factors.  Both disorders also share key clinical features including psychosis, neurocognitive impairment, and suicidality.  During this presentation, Roy Perlis, MD, MSc will discuss recent findings in genetic studies of schizophrenia and bipolar disorder, as well as examine their implications on diagnostic tools and treatment. Plan to attend this session to gain insight into the future role of genetics in psychiatry.

learn more

1.0
Registration closed.
04/30/2012 - 04/30/2015 Movement Disorders An Overview of Drug-Induced Movement Disorders ACPE
This 2-hour, 2-part interactive presentation provides an excellent opportunity to gain a comprehensive review ...[more]

This 2-hour, 2-part interactive presentation provides an excellent opportunity to gain a comprehensive review of drug-induced movement disorders for both new practitioners and experienced clinicians alike. Utilize movement disorder rating scales to be able to recognize and evaluate the signs and symptoms of pseudoparkinsonism, akathisia, and tardive dyskinesia. Hone your clinical assessment skills with CPNP Movement Disorder DVD speakers Roger W. Sommi, Jr., and Steven C. Stoner in hour two of this session offering application of concepts via cases.

learn more

1.0
Registration closed.
04/30/2012 - 04/30/2015 Movement Disorders Clinical Assessment of Drug-Induced Movement Disorders: A Case-Based Approach ACPE
This 2-hour, 2-part interactive presentation provides an excellent opportunity to gain a comprehensive review ...[more]

This 2-hour, 2-part interactive presentation provides an excellent opportunity to gain a comprehensive review of drug-induced movement disorders for both new practitioners and experienced clinicians alike. Utilize movement disorder rating scales to be able to recognize and evaluate the signs and symptoms of pseudoparkinsonism, akathisia, and tardive dyskinesia.  Hone your clinical assessment skills with CPNP Movement Disorder DVD speakers Roger W. Sommi, Jr., and Steven C. Stoner in hour two of this session offering application of concepts via cases.

learn more

1.0
Registration closed.
04/29/2012 - 04/29/2015 Bariatric Surgery: Nutritional and Pharmacologic Considerations in the Psychiatric Patient ACPE
The use of bariatric surgery as a treatment option for obesity is increasing. Approximately one-third of bariatric surgery patients ...[more]

The use of bariatric surgery as a treatment option for obesity is increasing. Approximately one-third of bariatric surgery patients are taking psychotropic medications, emphasizing the need for psychiatric pharmacists to understand the implications of these procedures on psychotropic medication dosing. Depending on the type of surgery performed, there can be absorption issues involving both vitamin/nutritional management and medication dosage formulations. This presentation will discuss contemporary bariatric surgical procedures and their implications on absorption kinetics and nutritional deficiencies, with a focus on post-surgical neurological complications. Evidence-based recommendations for vitamin/ nutritional management, as well as appropriate medication dosage forms pertinent to psychotropic medications will be reviewed.

learn more

1.0
Registration closed.
04/29/2012 - 04/29/2015 Making Sense of Antidepressants: An Evidence-Based Approach to the Controversies ACPE
The controversies surrounding the use of antidepressants in the treatment of depressive disorders have rocked the world of ...[more]

The controversies surrounding the use of antidepressants in the treatment of depressive disorders have rocked the world of psychiatry. From black box warnings to heated debates about efficacy in leading medical journals, this topic is sure to be timely and thought provoking. Nassir Ghaemi, MD, MPH will present Making Sense of Antidepressants: An Evidence-Based Approach to the Controversies on Sunday. Dr. Ghaemi is a world renowned leader in the treatment of mood disorders and author of A First-Rate Madness: Uncovering the Links Between Leadership and Mental Illness. After his presentation, you will have the chance to meet with Dr. Ghaemi and purchase a signed copy of this provocative book! Right now you can watch an interview with Dr. Ghaemi on The Colbert Report.

learn more

1.0
Registration closed.
04/29/2012 - 04/29/2015 Nicotine and Schizophrenia: Exploring the Relationship to Cognitive Function ACPE
Schizophrenia is a devastating, lifelong disease. There is accumulating evidence suggesting the involvement of the nicotinic system ...[more]

Schizophrenia is a devastating, lifelong disease. There is accumulating evidence suggesting the involvement of the nicotinic system in the pathophysiology of schizophrenia. This, in conjunction with a high rate of cigarette smoking among people with schizophrenia, introduces an interesting convergence of research and clinical treatment dilemmas around nicotine and schizophrenia.  Despite the evidence implicating the nicotinic system with symptoms of schizophrenia, no current treatment strategies focus on this system.  Additionally, smoking cessation programs in people with schizophrenia remain less than ideal.  During this session, Deanna Kelly, PharmD, BCPP will address the role of nicotine in cognitive function, and present emerging data on the effects of nicotinic agents on both cognition and smoking cessation.

learn more

1.0
Registration closed.
01/18/2012 - 12/31/2013 2012-2013 Psychiatric Pharmacy Review Course - ACPE Credit Only ACPE
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of ...[more]

The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care.

learn more

1.0 - 20.0
Registration closed.
05/04/2011 - 05/04/2014 The FDA: Inside the Black Box-A Discussion of Regulations and Recent Decisions ACPE
The Federal Food Drug and Cosmetic act states that approval of a drug requires “substantial evidence” from ...[more]

The Federal Food Drug and Cosmetic act states that approval of a drug requires “substantial evidence” from “adequate and well-controlled investigations”. The Code of Federal Regulations (CFR) codifies the FD&C Act and provides more details regarding what are considered to be adequate and well-controlled investigations. Guidance documents were developed to provide more detailed information, many times specific to the indications being studied, on various topics including clinical trial designs.

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Aggression in Children and Adolescents ACPE
Children and adolescents with psychiatric disorders may exhibit pathologic aggression that may be destructive, severe, chronic, and ...[more]

Children and adolescents with psychiatric disorders may exhibit pathologic aggression that may be destructive, severe, chronic, and unresponsive to psychosocial/ psychopharmacological treatment of their underlying pathology as well as to psychosocial interventions specifically targeting aggression. For this subset of aggressive youth, targeted pharmacotherapy may be appropriate. Evidence is growing to support the use of medications to manage aggressive behaviors across various childhood and adolescent psychiatric disorders. Safety should be emphasized when prescribing medication for these patients. However, serious health and safety risks are also raised when aggression is not effectively managed. This session will review the etiology, phenomenology, and treatment modalities for aggression in children and adolescents, and invoke discussion on best practices to clinically manage aggression in this population. The discussion will highlight evidence-based interventions and expert consensus recommendations, both pharmacologic and nonpharmacologic, and their relative effectiveness.

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Emerging Therapies for Multiple Sclerosis ACPE
This session reviews new knowledge in the pathophysiology of multiple sclerosis (MS) and describes how this knowledge informs drug ...[more]

This session reviews new knowledge in the pathophysiology of multiple sclerosis (MS) and describes how this knowledge informs drug therapy development for both immunomodulatory and symptomatic treatment.  Great strides in knowledge of MS pathophysiology have occurred over the last decade.  The role of B and T cells, other immune cells and tissues, and neurodegeneration are described. 

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Incorporating Health Services Research: Explaining Conceptual Frameworks Used by Researchers ACPE
Health services research involves the study of the impact of health care organization, financing, and delivery on access, quality, ...[more]

Health services research involves the study of the impact of health care organization, financing, and delivery on access, quality, outcomes and costs of patient care. It is a multidisciplinary field that employs a wide range of research methods that come from disciplines including but not limited to clinical epidemiology, sociology, economics, and organizational psychology. Still, what brings many of these disciplines together is the application of a common framework towards improving quality of care and reducing disparities in health outcomes. The objectives of this presentation is to describe some of the more common conceptual frameworks used by health services researchers, focusing in particular on  emerging frameworks that have been applied to the field of mental health services research, and how clinical and administrative data can be used to address unanswered questions based on these frameworks. The presentation will provide a roadmap for applying the Health Disparities Framework in detecting, understanding, and intervening on gaps in medical outcomes among patients with mental disorders. In addition, the presentation will describe the application of the Replicating Effective Programs framework to implementing patient-centered and psychosocial interventions to reduce disparities in mental disorders, as well as discuss the application of the emerging field of implementation science in facilitating the uptake of evidence-based practices for patients with mental disorders.

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Incorporating Health Services Research: Impact, Tools and the Future ACPE
The value of Health Services Research (HSR) extends far beyond opportunities for publication and advancement among academicians. ...[more]

The value of Health Services Research (HSR) extends far beyond opportunities for publication and advancement among academicians. Once an infrastructure for conducting HSR has been constructed, psychiatric pharmacists can use measured outcomes to directly influence patient care, justify clinical services, and ultimately advance the profession.

One of the best examples of the role HSR may serve in expanding psychiatric pharmacy practice can be found in the area of depression. Over the past decade there has been a determined research focus placed upon systematic efforts to improve the outcomes of depressed patients, including educational campaigns, web-based monitoring and collaborative care arrangements. Several investigations aimed at improving outcomes have featured psychiatric pharmacists in pivotal roles. While the results of these HSR efforts have generally been favorable, the scientific rigor of these investigations has varied considerably and the translation of these findings into practice has not been forthcoming.

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Irritability and Elation: The Consequences of Thinking about Pediatric Bipolar Disorder and Sever Mood Dysregulation ACPE
Severe mood dysregulation (SMD) is a relatively common childhood syndrome characterized by three features: chronic anger and ...[more]

Severe mood dysregulation (SMD) is a relatively common childhood syndrome characterized by three features: chronic anger and irritability, recurrent explosive outbursts, and the non-specific hyperarousal symptoms from the “B criteria” for mania including insomnia, agitation, distractibility, pressured speech, racing thoughts, and intrusiveness. Initially, SMD was proposed as an attempt to operationalize a definition of the “broad phenotype” of pediatric bipolar disorder (BD).  In an effort to test the assumption that SMD is a developmental form of BD, we examined the clinical course, family history, and neurobiology of individuals with SMD and compared them to pediatric patients with strictly defined DSM-IV BD. Current evidence to guide the pharmacologic treatment of SMD is extremely limited. Patients with SMD may benefit from targeting symptoms or features such as depression, anxiety, and attention-deficit/hyperactivity disorder, but more research is needed on pharmacologic and psychotherapeutic approaches to treatment.

learn more

1.0
Registration closed.
05/03/2011 - 05/03/2014 Seizures and Psychiatry ACPE
During the past few years, the comorbidity of affective disorders and epilepsy has been “re-discovered”. This ...[more]

During the past few years, the comorbidity of affective disorders and epilepsy has been “re-discovered”. This comorbidity has implications not only in antiepileptic drug (AED) selection, may also shed insight into the pathophysiology of this disorder. This presentation will discuss current treatment choices for various seizure disorders, along with a brief discussion regarding common psychiatric uses of various marketed AED. Common pathophysiological mechanisms of epilepsy and depression will be discussed, as well as an update on current perspectives regarding suicide risk with AEDs.

learn more

1.0
Registration closed.
05/02/2011 - 05/02/2014 Drug Transporters and Psychiatry ACPE
Drug transporters, especially P-glycoprotein, play an important role in drug delivery.  During this presentation, basic ...[more]

Drug transporters, especially P-glycoprotein, play an important role in drug delivery.  During this presentation, basic pharmacokinetic concepts are reviewed.  Then, the discussion on drug transporters and p-glycoprotein begins.  This discussion will address therapeutic implications in clinical practice of drug transporters along with literature regarding this topic.  The presentation will conclude with a summation of the topics discussed and audience participation.

learn more

1.0
Registration closed.
05/02/2011 - 05/02/2014 Impact of Psychotropic Medications on Sleep Architecture ACPE
Sleep, a universal feature of complex organisms, is regulated through the influence of numerous neuromodulatory pathways. This ...[more]

Sleep, a universal feature of complex organisms, is regulated through the influence of numerous neuromodulatory pathways. This presentation will provide an overview of sleep physiology, architecture, and physiological variability of sleep. The relationship between changes in sleep architecture and the subjective complaints of patients will be discussed, as well as the impact of psychiatric and neurological illness on sleep architecture in drug-naïve patients. The impact of psychotropic medications on sleep architecture will be reviewed class-by-class. Case vignettes will be evaluated to apply the content and illustrate the clinical relevance of the complex relationship of sleep and treatment of psychiatric illness.

learn more

1.0
Registration closed.
05/02/2011 - 05/01/2014 Medico-Legal Considerations in the Management of Behavioral Disturbances in the Elderly ACPE
This presentation will provide participants an overview of the medico-legal considerations regarding treatment of neuropsychiatric ...[more]

This presentation will provide participants an overview of the medico-legal considerations regarding treatment of neuropsychiatric symptoms in patients with dementia.

learn more

1.0
Registration closed.
05/02/2011 - 05/01/2014 Pharmacological Management of Behavioral Disturbances in the Elderly ACPE
This presentation will provide participants an overview of the current evidence regarding treatment of neuropsychiatric symptoms in ...[more]

This presentation will provide participants an overview of the current evidence regarding treatment of neuropsychiatric symptoms in patients with dementia. The presentation will follow the recommendations from the American College of Neuropsychopharmacology (ACNP) white paper. Before initiating treatment for behavioral symptoms in patients with dementia, differential diagnosis is necessary. Once other causes of the behavior are ruled out, nonpharmacologic treatments should be initiated before starting pharmacologic treatment. Several nonpharmacologic treatments and literature supporting efficacy will be discussed. Finally drug therapy will be discussed focusing on antipsychotic medications, adverse effects, and the results of the CATIE-AD trial. During this presentation  the audience will have several opportunities to interact and participate in discussions of case presentations using Poll Everywhere technology.

learn more

1.0
Registration closed.
05/02/2011 - 05/02/2014 Seizing the MTM Opportunity: What Psychiatric Pharmacists Need to Know ACPE
This presentation will focus on how the health care system is changing and how psychiatric pharmacists need to adapt to these ...[more]

This presentation will focus on how the health care system is changing and how psychiatric pharmacists need to adapt to these changes to be successful.  The objectives for the presentation will be to; a) understand the changing environment, b) adopt terminology that has currency in the new system, c) understand the new rules and regulations, d) be able to recognize success under the new rules, and e) decide which direction for the future is best.  The specific changes that impact psychiatric pharmacists will be presented and the consequences of these changes discussed.

learn more

1.0
Registration closed.
05/02/2011 - 05/02/2014 Use of Omega-3 Fatty Acids in Mental Illness ACPE
Omega-3 fatty acids are involved in many physiologic processes. Since they cannot be made de novo in the body, they are considered ...[more]

Omega-3 fatty acids are involved in many physiologic processes. Since they cannot be made de novo in the body, they are considered essential nutrients and are divided into two groups 1) short chain, alpha linolenic acid (ALA) and 2) long chain, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fatty acids. The long chain omega-3 fatty acids are derived from marine sources such as oily fish and are more frequently implicated in mental illness than ALA.

learn more

1.0
Registration closed.
05/01/2011 - 05/01/2014 Fibromyalgia: Pain and the Brain ACPE
This presentation will discuss the prevalence, clinical presentation, pathophysiology diagnosis and treatment of fibromyalgia ...[more]

This presentation will discuss the prevalence, clinical presentation, pathophysiology diagnosis and treatment of fibromyalgia syndrome (FMS). While not completely understood, disordered central pain processing likely plays a role in the pathogenesis of FMS and treatment strategies primarily focus on alleviating pain and addressing associated symptoms and comorbid conditions.

learn more

1.0
Registration closed.
05/01/2011 - 05/01/2014 Putting the Action in Long-Acting Antipsychotic Injections ACPE
Since the development and introduction of the long-acting antipsychotic medications in the 1960’s, clinical debates have ...[more]

Since the development and introduction of the long-acting antipsychotic medications in the 1960’s, clinical debates have occurred among health-care providers as to when these medications are appropriate to use.  The impact of poor medication adherence among patients with psychiatric disorders has a great impact on their clinical outcomes.  Long-acting injectable antipsychotics have been shown to reduce hospitalizations and to improve medication adherence.  The clinical pharmacologic properties, safety and tolerability profiles of these medications vary between agents.

learn more

1.0
Registration closed.
05/01/2011 - 05/01/2014 The Role of Antidepressants in Bipolar Disorder: Myth vs. Reality ACPE
The safety and efficacy of antidepressants for patients with bipolar disorder continues to remain a source of tremendous ...[more]

The safety and efficacy of antidepressants for patients with bipolar disorder continues to remain a source of tremendous controversy.  Initial reports of antidepressant-induced mania or hypomania led to marked concern among practitioners that antidepressants were highly likely to destabilize mood and worsen the course of illness in most people with bipolar disorder.  More recent investigations indicate that the potential for antidepressants to cause mania or hypomania is a rarer phenomenon than originally thought, occurring in about 10-15% of bipolar disorder patients.  Moreover, studies from the past two decades identify patient-specific risk factors for the emergence of antidepressant-associated mania or hypomania, suggesting its potential significance as an illness endophenotype.  Clinical studies suggest that the risk for mood destabilization from antidepressants appears higher in individuals with bipolar I (rather than bipolar II) disorder, as well as those with concomitant manic/hypomanic symptoms during depressive illness phases, recent manic or hypomanic episodes, comorbid alcohol or drug abuse, and past histories of antidepressant-induced mood destabilization.  Furthermore, risk may be somewhat higher with noradrenergic antidepressants (such as tricyclics or serotonin/norepinephrine reuptake inhibitors) than with purely serotonergic or primarily dopaminergic agents.  Co-therapy with antimanic drugs such as lithium may not reliably mitigate the risk for antidepressant-induced mania or hypomania.

learn more

1.0
Registration closed.
04/21/2010 - 04/21/2013 Strategies to Develop Disease Modifying Drugs: Focus on Alzheimer’s and Surrogate Endpoints ACPE
Delve into a discussion of leading biosurrogate markers in the area of Alzheimer’s Disease (AD). The discussion includes a ...[more]

Delve into a discussion of leading biosurrogate markers in the area of Alzheimer’s Disease (AD). The discussion includes a review of the current state of the art for disease modifying drugs, a review of research design methodology as it relates to AD and case illustrations for early drug development as targets for the therapeutics of AD.

learn more

1.0
Registration closed.
04/21/2010 - 04/21/2013 Treatment of Cognitive Impairment in Schizophrenia ACPE
Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with ...[more]

Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with deficits in cognitive functioning. Cognitive enhancement has been proposed as a pathway to disability reduction. This pathway has been clearly defined in terms of the required clinical trials methods, with primary (cognitive) and secondary (functional) outcome measures well validated. Second generation (Newer, Atypical) antipsychotic medications have been thoroughly evaluated with their cognitive enhancement potential.

learn more

1.0
Registration closed.
04/20/2010 - 04/20/2013 Efficacy vs. Adverse Effects: Which Trumps? Point-Counterpoint ACPE
Although first generation antipsychotics (FGAs) provided the bedrock of clinical treatment for people with schizophrenia for over ...[more]

Although first generation antipsychotics (FGAs) provided the bedrock of clinical treatment for people with schizophrenia for over 30 years, the advent of successive new drugs- second generation antipsychotics (SGAs)- led to a decline in use of FGAs in favor of SGAs that were (at least initially) perceived as both more efficacious and better tolerated.  While the relative merits of FGAs and SGAs remain hotly debated, it is now clear that the selection of an appropriate antipsychotic for any given patient represents a highly complex clinical decision-making process.

learn more

2.0
Registration closed.
04/20/2010 - 04/20/2013 Genetic Epidemiology of Early-Onset Depression and Alcohol Use Disorders ACPE
Alcohol-related deaths are the leading cause of mortality in adolescents.  Unfortunately alcohol-use disorders (AUD) are also ...[more]

Alcohol-related deaths are the leading cause of mortality in adolescents.  Unfortunately alcohol-use disorders (AUD) are also the most prevalent of the substance-use disorders in adolescents and less than 10% of the numbers of adolescents who meet criteria for alcohol treatment actually receive treatment.  Current treatments for adolescent AUD are primarily non-pharmacologic. However, recent genetic epidemiology research suggests the combined role of genes and environment in adolescent AUD.  Furthermore, Research in the role of stress response suggests emerging targets for pharmacologic interventions.

learn more

1.0
Registration closed.
04/20/2010 - 04/20/2013 Management of Psychiatric Illness in HIV Patients: A Major Treatment Dilemma ACPE
Over 1 million people are living with HIV in the United States. Transmission is on the rise in women, Blacks, Hispanics, ...[more]

Over 1 million people are living with HIV in the United States. Transmission is on the rise in women, Blacks, Hispanics, heterosexuals, adolescents and elderly. People with human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome have high rates of psychiatric illness. The effective management of these psychiatric conditions can improve a patient's quality of life and may improve antiretroviral adherence.

learn more

1.0
Registration closed.
04/19/2010 - 04/19/2013 Improving Outcomes in Patients with Traumatic Brain Injury ACPE
Traumatic brain injury (TBI) is a significant health problem in the United States, and a frequent cause of disability in young ...[more]

Traumatic brain injury (TBI) is a significant health problem in the United States, and a frequent cause of disability in young individuals.   The Wars in Iraq and Afghanistan have heightened the public awareness of this condition and resulted in an increasing number of individuals presenting for treatment due to concern of a suspected TBI.  In order to best manage the sequelae of TBI, providers must understand important prognostic factors which impact clinical outcome including injury severity and co-morbid conditions.

learn more

1.0
Registration closed.
04/19/2010 - 04/19/2013 Life After Star*D: Lessons Learned and the Next Steps for Managing Depression ACPE
Major depression is a complex disorder, with as many as 50% of patients non-responsive to initial antidepressant therapy.  The ...[more]

Major depression is a complex disorder, with as many as 50% of patients non-responsive to initial antidepressant therapy.  The NIMH sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) set out to determine what the next “best step” was for patients not responding adequately to one or more prior treatments.  In addition, given the large, representative patient sample and comprehensive data collected, STAR*D was able to provide clinical and genetic predictors of treatment outcomes.

learn more

1.0
Registration closed.
04/19/2010 - 04/19/2013 Long-Term Effect of In-Utero Exposure to Psychotropic Medications ACPE
This one hour session will discuss the currently known risk of malformations, pregnancy outcomes, and neurodevelopment after ...[more]

This one hour session will discuss the currently known risk of malformations, pregnancy outcomes, and neurodevelopment after maternal use of antidepressants, antipsychotic, and traditional mood stabilizers.  We will also discuss data types used to determine safety of medications during pregnancy while highlighting the National Register of Antipsychotic Medications in Pregnancy (NRAMP) and the North American Pregnancy Registry.  Finally, this presentation will provide tools for patient education to help discuss risk versus benefit of psychotropic medication use in pregnancy.

learn more

1.0
Registration closed.
04/19/2010 - 04/19/2013 Strategies for the Management of Treatment-Resistant Depression ACPE
Treatment resistant depression (TRD) has gotten increased attention given the higher than anticipated incidence demonstrated by the ...[more]

Treatment resistant depression (TRD) has gotten increased attention given the higher than anticipated incidence demonstrated by the STAR*D trial and the availability of novel pharmacological and other somatic therapies.  The difficulties in addressing TRD are magnified by a high incidence of misdiagnosis.  The primary sources for misdiagnoses are inadequate treatment, missed diagnoses of bipolarity or psychosis and medical co-morbidities.  Approaches to improve differential diagnosis will be discussed.

learn more

1.0
Registration closed.
04/19/2010 - 04/19/2013 The Role of Folate in Depression and Dementia: The Burden of Vitamin Deficiency ACPE
It is well know that folate is essential for the development and normal function of the central nervous system (CNS).  This is ...[more]

It is well know that folate is essential for the development and normal function of the central nervous system (CNS).  This is illustrated by the many cases of in-born errors of folate metabolism which lead to profound deleterious effects in the CNS.  The neuropsychiatric complications of folate deficiency from various causes are remarkably similar to those described for vitamin B12 deficiency, but the former is particularly associated with depression and dementia especially in the elderly. Inherited and acquired disorders of folate and B vitamin metabolism are often associated with neurological and psychiatric complications.

learn more

1.0
Registration closed.
04/18/2010 - 04/18/2013 In a World of Their Own: Diagnosis and Treatment of Autism ACPE
Pervasive developmental disorders (PDDs) are neuropsychiatric disorders characterized by social and communication impairments, as ...[more]

Pervasive developmental disorders (PDDs) are neuropsychiatric disorders characterized by social and communication impairments, as well as repetitive interests and activities.  The five PDD include Autistic Disorder, Asperger’s Disorders, Rett’s Disorder, Childhood Disintegrative Disorder, and PDD Not Otherwise Specified. Children and adolescents diagnosed with PDDs often suffer from a number of target symptoms that require pharmacologic treatment.  Symptoms frequently include hyperactivity and inattention, ritualistic and repetitive behavior, and irritability (aggression, self-injury, tantrums).  The purpose of this presentation is to review the diagnosis and treatment of PDDs.

learn more

1.0
Registration closed.
04/18/2010 - 04/18/2013 New Drugs and Formulations in Psychiatry: Critical Analysis in Formulary Decision-Making ACPE
Potential additions to health system formularies are reviewed for safety, efficacy, therapeutic need, and cost.  Formularies ...[more]

Potential additions to health system formularies are reviewed for safety, efficacy, therapeutic need, and cost.  Formularies in mental health have separate issues that must be considered.  Clinical decision-making without knowledge from well-designed, controlled, randomized trials with adequate sample size, can incorrectly estimate the efficacy and safety risks associated with specific drug therapy.  The practice of evidence-based medicine (EBM) involves integrating clinical expertise with the best available evidence from systematic research.

learn more

2.0
Registration closed.
01/29/2010 - 06/30/2012 2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only ACPE
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of ...[more]

The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care.

learn more

1.0 - 20.0
Registration closed.
04/22/2009 - 04/22/2012 Dosage Formulation Technologies for Antipsychotics: The Edge of the Pharmacokinetic-Pharmacodynamic Interface ACPE
Dosage formulation technologies are undergoing a renaissance, spanning nanotechnology, polymer chemistry, aerosolization, and smart ...[more]

Dosage formulation technologies are undergoing a renaissance, spanning nanotechnology, polymer chemistry, aerosolization, and smart skin patches. The development of new dosage formulations of antipsychotic medications, focuses upon modified oral release, ultra-fast acting inhalation, and long-acting injectable therapies.  

learn more

1.0
Registration closed.
04/22/2009 - 04/22/2012 Pharmacogenomics Primer and Update ACPE
At the intersection of pharmacology and genetics is pharmacogenetics or pharmacogenomics. This rapidly evolving field is one of the ...[more]

At the intersection of pharmacology and genetics is pharmacogenetics or pharmacogenomics. This rapidly evolving field is one of the cornerstones of Personalized Medicine, however many health care providers do not feel comfortable with the science behind this field nor with the ambiguity in the data that is currently available to support mainstream integration of this field into practice. Thus, the goal of this presentation is to briefly review some of the genetic principals that underlie the field of pharmacogenomics so that health care providers may feel more comfortable in reviewing this literature and be able to understand how to incorporate this science into their practice.

learn more

1.0
Registration closed.
04/21/2009 - 04/21/2012 Delirium and its Management: Focus on Anticholinergics ACPE
Delirium is a state of acute confusion resulting from a general medical condition that can last from hours to months, often ...[more]

Delirium is a state of acute confusion resulting from a general medical condition that can last from hours to months, often fluctuates in severity and presentation, and may include a variety of psychiatric symptoms. It is particularly common in the elderly and those with pre-existing cognitive impairment or brain injury. Delirium is a predictor of multiple adverse outcomes, including functional and cognitive decline, increased length of hospitalization, and mortality.

learn more

1.0
Registration closed.
04/21/2009 - 04/21/2012 Dispelling the Myths: Point-Counterpoint Debate on European and US Treatment Guidelines for Bipolar Disorder ACPE
Bipolar disorder affects approximately 1% of the worldwide population. Several pharmacologic options are available to treat this ...[more]

Bipolar disorder affects approximately 1% of the worldwide population. Several pharmacologic options are available to treat this condition and treatment guidelines are available to direct treatment. Common treatment guidelines in the United States include the American Psychiatric Association guidelines, the Expert Consensus Guidelines, and the Texas Implementation of Medical Algorithms for Bipolar Disorder treatment algorithm, while European guidelines include the European Collegeof Neuropsychopharmacology (ECNP) Consensus Statement on Bipolar Disorder and the National Institute for Health and Clinical Excellence (NICE) guidelines.

learn more

2.0
Registration closed.
04/21/2009 - 04/21/2012 Movement Disorders: Focus on Dystonias and Tremor ACPE
Idiopathic dystonia and tremor disorders are movement disorders that are underrecognized or undertreated. Familiarity with the ...[more]

Idiopathic dystonia and tremor disorders are movement disorders that are underrecognized or undertreated. Familiarity with the clinical features and available treatments will allow clinicians to better identify and manage patients with dystonia or tremor disorders. This session will utilize video cases as learning tools.

learn more

1.0
Registration closed.
04/21/2009 - 04/21/2012 Treatment of Alcohol Dependence Complicated by Depression and Anxiety Spectrum Disorders ACPE
Psychiatric disorders frequently co-occur with alcohol dependence. The National Epidemiologic Survey on Alcohol and Related ...[more]

Psychiatric disorders frequently co-occur with alcohol dependence. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) confirms previous epidemiologic data that bipolar disorder has the highest co-occurrence with alcoholism, followed by major depression, generalized anxiety disorder, and social anxiety. Although these disorders frequently co-occur, there are few studies evaluating the treatment of these comorbid conditions. The studies that are available typically focus on the treatment of the underlying psychiatric disorder.

learn more

1.0
Registration closed.
04/20/2009 - 04/20/2012 Adult ADHD: Beyond Childhood ACPE
Attention Deficit Hyperactivity Disorder is a common neuropsychiatric condition impacting 4.4% of the adult population age 18-44 ...[more]

Attention Deficit Hyperactivity Disorder is a common neuropsychiatric condition impacting 4.4% of the adult population age 18-44 according to a recent epidemiological survey. As in childhood, the condition is often marked by challenges with attention, organization and forgetfulness, although adults who were hyperactive as children often grow out of physical hyperactivity. There is evidence that ADHD is associated with poorer outcomes in domestic and occupational endeavors, as well as higher rates of motor vehicle accidents.

learn more

1.0
Registration closed.
04/20/2009 - 04/20/2012 Cortical Development in Attention-Deficit/Hyperactivity Disorder and the Impact of Psychostimulants ACPE
There have been great advances in understanding the neurobiology of ADHD.  While there appears to be some overall reduction in ...[more]

There have been great advances in understanding the neurobiology of ADHD.  While there appears to be some overall reduction in brain volumes in children with ADHD, several richly interconnected brain areas seem to be particularly affected- the prefrontal cortex, the basal ganglia and the cerebellum.  In addition recent longitudinal studies suggest that ADHD can be understood in part as due to a delay in cortical maturation.

learn more

1.0
Registration closed.
04/20/2009 - 04/20/2012 Fibromyalgia: An Update on Diagnosis and Treatment Strategies ACPE
Fibromyalgia is a widespread chronic pain syndrome characterized by diffuse musculoskeletal achiness, stiffness, and exaggerated ...[more]

Fibromyalgia is a widespread chronic pain syndrome characterized by diffuse musculoskeletal achiness, stiffness, and exaggerated tenderness. Current view of the condition indicates that it is a huge continuum of pain and somatic syndromes. It is believed that increase sensitization of the central nervous system to sensory modalities results in the development of many of the symptoms of fibromyalgia. The etiology of fibromyalgia is currently unknown but research is accumulating that indicates that it is most likely multifactorial.

learn more

1.0
Registration closed.
04/20/2009 - 04/20/2012 Management of Depression in Post-stroke Patients ACPE
Although the prevalence of PSD depends upon whether the patients are examined in community settings or acute hospitals, the mean ...[more]

Although the prevalence of PSD depends upon whether the patients are examined in community settings or acute hospitals, the mean prevalence of major depressive disorder based on pooled data from the world’s literature is 20% during acute poststroke period for major depression and 19% for minor depression.  The diagnosis of depression is based on DSM-IV criteria for major or minor depression.  There is relatively little effect of physical illness on the manifestations of depressive symptoms.  The major risk factors for developing poststroke depression include severity of impairment in activities of daily living, in cognitive function and in social support.

learn more

1.0
Registration closed.
04/20/2009 - 04/20/2012 Non-Pharmacological Interventions for Schizophrenia ACPE
While there is no doubt that medication treatments have demonstrated efficacy for improving clinical symptoms and decreasing rates ...[more]

While there is no doubt that medication treatments have demonstrated efficacy for improving clinical symptoms and decreasing rates of relapse for individuals with schizophrenia, many aspects of the illness have not responded or have only partially responded to pharmacotherapy. Multiple psychosocial treatments have been pursued to address these needs. This presentation will focus on two primary types of treatment:  Cognitive Behavior Therapy (CBT) and Cognitive Rehabilitation. CBT is designed to decrease the frequency, severity, and the impact on functional outcome of positive symptoms that persist despite adequate medication treatment.

learn more

1.0
Registration closed.
04/19/2009 - 04/19/2012 Antidepressants and Suicide Risk in Children and Adults: Using Evidence to Separate Fact from Fiction ACPE
Suicide is considered rare in non-depressed individuals but it occurs in between 5 and 15% of those suffering from ...[more]

Suicide is considered rare in non-depressed individuals but it occurs in between 5 and 15% of those suffering from depression.  The Columbia Suicide Severity Rating Scale (C-SSRS) is recommended for assessing an individual patient’s suicide risk.  Suicide risk factors in children, adolescents and adults include untreated depression, psychosis, access to firearms. Additional factors that increase suicide risk in children and adolescents include maternal depression, witnessing suicide attempts or sexual abuse or experiencing sexual abuse or trauma themselves.  Cyber-bullying is becoming more recognized as a contributing factor to suicide in youth.

learn more

1.0
Registration closed.